Table Of Content

Hariparsad N, 1273 Jusko WJ, 991, 1034 Lasseter KC, 1054 Mayer PR, 873, 1235 Harmatz JS, 605 Juszczyk J, 338 Lau DTW, 495 Mayersohn M, 1151 Hartford A, 487, 1054 Kadota R, 1309 Laurent A, 193 Mazenko RS, 48, 1125 Harvey AT, 1173 Kalbag J, 646 LaVallee N, 510 McCrea JB, 305 Hashem M, 1328 Kalies I, 928 Le Coz F, 1244 McCurry K, 135 Haskell LP, 621 Kamal MA, 1034 Leclerc V, 234 McDade K, 135 Hayes MJ, 158 Kaneda A, 538 Lee D, 767 McLeod JF, 120 He W, 1054 Kaneko S, 538 Lee JS, 1166 Mehendale SR, 1323 Hebert MF, 89 Kang Y-K, 1166 Lee L, 599 Mehring G, 158 Heinpalu M, 1143 Kantesaria B, 1252 Lee SSCL, 632 Menchaca D, 495 Henkel T, 590 Karyekar CS, 919 Lee Y, 215 Metzger D, 543 Heo YS, 1166 Kashuba ADM, 570, 708 Leeder JS, 708 Meverrose GE, 150 Hermann R, 510 Katneni K, 723 Leese P, 646 Michael J, 1328 Hermida J, 974 Kato M, 890 Lefebvre M, 640 Michiels N, 1125 Herron J, 1252 Katzper M, 368 Lehmann D, 861 Mignot A, 1114 Hewitt RG, 293 Kays MB, 1012 Lehtonen L, 1143 Migoya E, 487 Hichwa RD, 751 Kazierad DJ, 457 Leibowitz MT, 258 Miller JL, 1125 Hirano T, 481 Kearns GL, 487 Lensing P, 837 Millerioux L, 1114 Hochhaus G, 510 Keefe DL, 679 Leroy B, 234 Milosavljev S, 193, 646 Hoelscher D, 689 Kennedy MJ, 708 Lesko LJ, 559 Minton N, 991 Hoffer C, 224 Kessler E, 388, 935 Levy RH, 1230 Mivaoka M, 481 Hogerzeil HV, 1106 Khalil MH, 1132 Lew RA, 457 Mochizuki H, 890 Holdbrook F, 981 Kharasch ED, 224 Lewanczuk RZ, 245 Moncrief JW, 48 Holloway K, 1106 Khetani VD, 173 Li Q, 577 Montay G, 234 Hossain M, 599 Kim JS, 570 Li W-B, 785 Moon B-S, 73 Howell SR, 379 Kim K, 1083 Li Z,. 577 Morganroth J, 689 Hu P, 1260 Kim M-J, 570, 696, 966 Lim H-S, 73 Morimoto T, 95 Huang M, 1023 Kim SB, 1166 Lin C-C, 265 Moriyasu F, 481 Huang S-M, 559 Kim SC, 743 Linke R, 866 Moser L, 1328 Hubbard RC, 474 Kim TW, 1166 Liu J, 577 Motte J, 1290 Hughes D, 680 Kim WK, 1166 Liu L, 1054 Mottern RK, 359 Hunt T, 532 Kinchelow T, 793 Ljungqvist A, 293 Mudaliar S, 414 Hunt TL, 83, 503 Kink-Eiband M, 777 Lloyd P, 158 Murdoch RD, 1046 Hutin YJF, 1106 Kirkesseli S, 348 Locher M, 510 Murphy G, 1054 Huynh P, 7 Kitt M, 689 Logez SMD, 1106 Nafziger AN, 447, 570, 696, Iacono A, 135 Kleiman NS, 981 Loogna I, 1143 966 Imai H, 95 Kline WF, 48 Lou Y, 1301 Nakano S, 95 Ishkanian G, 1158 Knebel W, 590 Lowry R, 305 Nallani SC, 1273 Itoh M, 890 Knorr B, 487 Lu J, 1260 Natarajan J, 464 Iwabuchi K, 890 Koeppel J, 751 Ludden T, 590 Nave R, 37 Iwata R, 890 Kolis S, 793 Lyness WH, 258 Nelsen J, 861 Jabbour JT, 359 Korth-Bradley J, 543, 873, 1244 Ma JD, 447, 570 Neumayer H-H, 163 Jacobs L-D, 1282 Kotegawa T, 95 Ma T, 767 Newman N, 861 Jacobsen LV, 258 Kovarik JM, 532 Maglio D, 188 Nicolau DP, 188 Jamali F, 245 Kowey PR, 1063 Majumdar AK, 215 Noel GJ, 464 Jang I-J, 73 Kraft WK, 67, 305, 1125 Mallikaarjun S, 179 Noveck RJ, 474 Jeha S, 1309 Krause D, 590 Mamidi RNVS, 723 Obach RS, 7 Jenkins PL, 696 Krauwinkel WJ, 1023 Mann J, 59 Oertel R, 1282 Jensen BK, 348, 901 Kuritsch I, 777 Marbury T, 234 Oh JM, 743 Jhee SS, 258 Kusma SE, 305 Marbury TC, 48 Ohlsson L, 928 Jiang H, 1260 Kutz K, 59 Markabi S, 1290 Ohtani Y, 95 Jiang J, 1260 Kuzmak B, 373 Martin D, 1151 Oka K, 481 Jiang T, 1323 Lai A, 253 Martin LL, 379, 901 Okerholm RA, 253 Jiwatani S, 723 Lai AA, 83, 503 Martin NE, 379, 621, 901 O'Leary DS, 751 Jodynis-Liebert J, 338 LaLonde T, 1328 Massicotte J, 640 Onda K, 481 Johansson S, 388 Lam GN, 1309 Mathijssen RHJ, 854 Overholser BR, 1012 Johnson JA, 1083 Lamba J, 135 Matthews CZ, 48, 1125 Padmanabhan M, 464 Johnson M, 1301 Larson AM, 89 Matuszewska A, 338 Pairet M, 777 Palic B, 293 Roze J-C, 1114 Solanki B, 464 Valesky R, 1054 Pan W-], 1230 Russell A, 245 Song K-S, 73 van Adelsberg J, 487 Paolini JF, 1054 Russo R, 188 Sowers JR, 397 van Ryn J, 777 Paoluzzi L, 854 Ruxrungtham K, 793 Sowinski KM, 1012 Vargas R, 234 Parchman LG, 981 Rytting M, 1309 Sparreboom A, 854 Vega JM, 1054 Parisi S, 520 Ryu M-H, 1166 Spénard J, 640 Venkataramanan R, 743 Park JM, 89 Sack M, 234 Spencer E, 689 Venuto RC, 1003 Parks V, 543, 1244 Sack MR, 48 Srinivas ML, 723 Verweij J, 854 Patat A, 543, 1244 Saito M, 1223 Srinivas NR, 115, 723 von Moltke LL, 679 Patel IH, 793 Sakurada Y, 890 Staton BA, 276 Wacholtz MC, 991 Peng B, 158 Salazar DE, 179 Steiger B, 67 Wade A, 1158 Petty KJ, 48, 215 Sane RS, 1273 Stein DS, 1301 Wade M, 83, 503 Pfister M, 621 Sarich TC, 388, 935, 1063 Steinherz P, 1309 Wajdula J, 1235 Philips L, 265 Sarich TS, 928 Stiles M, 1132 Waldman SA, 67, 305, Pistner H, 1282 Sattler G, 1282 Stirling DI, 173 Wall U, 388, 928, 935 Planken U, 1143 Scavone JM, 605 Stogniew M, 590 Wallenstein G, 777 Plunkett W, 1309 Scharf MB, 253 Stoltz R, 520 Wang C-Y, 785, 1323 Poder P, 1143 Scheffler MR, 173 Sturm Y, 1290 Wang D, 577 Pokorny R, 158 Schinzel S, 1282 Stypinski D, 173 Wang L-S, 577 Pollak PT, 141 Schmerler M, 1230 Suarez JA, 150 Wang X, 881 Pons G, 1290 Schmitt BA, 751 Subramaniam S, 723 Wang Y, 532, 599, 646 Ponto LLB, 751 Schmouder R, 532 Sugawara K, 1223 Ward CA, 751 Pope LE, 1132 Schofield JP, 1046 Sundberg S, 1143 Watkins GL, 751 Porras AG, 48, 1125 Schreiber TL, 1328 Surath A, 723 Waye MMY, 582 Preskorn SH, 1173 Schuck EL, 837 Swan S, 48 Webber DM, 1046 Price DK, 854 Schuetz E, 135 Swan SK, 234 Webber S, 135 Prisant LM, 394, 406, 423 Schultz A, 1125 Swart PJ, 1023 Weber W, 163 Prueksaritanont T, 1054 Schur JL, 293 Szefler S, 37 Wehling M, 1125 Putcha L, 837 Schiitzer K-M, 388, 928, 935, 1063 Takahata T, 1223 Wei GC, 457 Qiu Y, 1054 Schwartz JI, 48 Tan K, 284 Weitman S, 1309 Quiring JN, 67 Scott G, 193, 646 Tang ZR, 577 Weng Y-Z, 785 Ragueneau-Majlessi I, 1230 Sedek G, 599 Tashiro M, 890 Werder S, 1173 Rajman I, 457 Seiberling M, 158 Tateishi T, 538, 1223 Whitaker A-M, 188 Ramakrishnan R, 991 Sekiguchi K, 284 Tay LK, 680 Whittington D, 224 Ramananth V, 861 Sellers EM, 966, 1132 Teng R, 388, 1063 Winchell GA, 305 Randall S, 1301 Shader RI, 605 Teo SK, 173 Winer N, 397 Rantanen S, 1143 Shadle CR, 215 Terra SG, 457 Wollbratt M, 935 Razzouk B, 1309 Shafer SL, 141 Thomas SD, 173 Wong DF, 890 Reed KA, 1003 Shah A, 520 Thompson GA, 373 Wong PH, 48 Reed RC, 737 Shah B, 348 Thon A, 866 Wong SL, 495 Rehan A, 1328 Shah J, 1230 Toma T, 481 Woolf EJ, 48, 305, 1125 Rey E, 1290 Shang Y, 881 Tomlinson B, 582 Worley DJ, 373 Richmond JCW, 751 Shelton MJ, 293 Tong Z, 120 Worth E, 951 Richter K, 1282 Shi J, 234 Tornatore KM, 1003 Wu A, 173 Ristich J, 135 Shimatani K, 284 Tozzi CA, 487 Wu J, 577 Riviere G-J, 532 Shin S-G, 73 Tran A, 1290 Xu C, 265 Robson RA, 48 Shon J-H, 73 Tremblay C, 640 Yakatan GJ, 1132 Rodriguez CA, 276 Shoyama Y, 1323 Trummlitz G, 777 Yamasaki H, 1328 Rohatagi S, 37, 348 Siebert-Weigel M, 510 Tsikouris JP, 150, 327 Yanai K, 890 Rojas PB, 258 Sigmund R, 163 Tsutsumi K, 95 Yasui-Furukori N, 538, 1223 Romanelli M, 1328 Simcoe D, 1244 Tuerck D, 866 Yeh C-M, 193 Rominger K-L, 163 Singh AS, 854 Tiirck D, 163 Yeh L-T, 265 RordorfC , 193, 646 Slowinski T, 163 Tutor JC, 974 ¥i:S-¥773 Roscigno R, 83, 503 Smith A, 861 Tutor-Crespo MJ, 974 Yih L, 193 Rosenfeld W, 1230 Smith J, 150 Uno' Tt, 1223 Yin OQP, 582 Roset PN, 30 Smulders RA, 1023 Uppalapati S, 723 Yu K-S, 73 Rosman HS, 1328 Soares-da-Silva P, 906 Upreti VV, 723 Yuan C-S, 1323 Rowland E, 570 Sobue S, 284 Jaldez J, 1151 Zaldonis D, 135 Zarotsky V, 258 Zhang X, 793 Zheng H, 135 Zhu J, 881 Zech K, 37 Zhang Y, 966 Zhou G, 577 Zhu R-H, 785 Zeevi A, 135 Zhang Z-J, 785 Zhou H, 120, 543, 1235, 1244 Ziska M, 150 Zeng Z, 348 Zhao J, 487 Zhou H-H, 577, 785 Zussman B, 1046 Zhai Y-M, 785 Zhao JJ, 1054 Zhou YS, 680 Zhang J, 135, 348 Zhao J-P, 785 Zhu B, 577 Subject Index, Volume 44 (2004) Abarelix Aminoglycoside-associated nephrotoxicity Antidepressives pharmacokinetics and pharmacodynamics of a application of Bayes theorem to aminoglycoside- DOV 216,303, “triple” reuptake inhibitor: safety, novel depot formulation of abarelix, a gonad- associated nephrotoxicity: comparison of ex- tolerability, and pharmacokinetic profile, otropin-releasing hormone (GnRH) antago- tended-interval dosing, individualized 1361 nist, in healthy men ages 50 to 75, 495 pharmacokinetic monitoring, and multiple- Antiemetic agents Absolute bioavailability daily dosing, 696 pharmacokinetic and safety evaluation of absolute bioavailability and pharmacokinetics of Amiodarone palonosetron, a 5-hydroxytryptamine-3 re- treprostinil sodium administered by acute a pharmacokinetic study of the combined admin- ceptor antagonist, in U.S. and Japanese subcutaneous infusion, 83 istration of amiodarone and ximelagatran, an healthy subjects, 520 Absorption oral direct thrombin inhibitor, 1063 Antifungal absorption of rivastigmine from different regions Amprenavir pharmacokinetics and safety of fosfluconazole af- of the gastrointestinal tract in humans, pharmacokinetic and pharmacodynamic analy- ter single intravenous bolus injection in ACE inhibitor sis of amprenavir-containing combination healthy male Japanese volunteers, 284 blood pressure control and nephroprotection in therapy in HIV-1-infected children, 1301 population pharmacokinetic analysis of diabetes, 431 Analgesia anidulafungin, an echinocandin antifungal, optimizing dose selection with modeling and analgesic effect of sustained-release flurbiprofen 590 simulation: application to the vasopeptidase administered at the site of tissue injury in the Antiplatelet inhibitor M100240, 621 oral surgery model, 1419 intense management of diabetes mellitus: role of pharmacokinetics of M100240 and MDL assessment of visual analog versus categorical glucose control and antiplatelet agents, 414 100,173, a dual angiotensin-converting en- scale for measurement of osteoarthritis pain, meloxicam does not affect the antiplatelet effect zyme/neutral endopeptidase inhibitor, in 368 of aspirin in healthy male and female volun- healthy young and elderly volunteers, 901 effect of modafinil on acute pain: a randomized teers, 777 pharmacological and clinical profile of double-blind crossover study, 1426 Antiretrovirals moexipril: a concise review, 827 efficacy of oxymorphone extended release in indinavir and rifabutin drug interactions in questioning a class effect: does ACE inhibitor tis- postsurgical pain: a randomized clinical trial healthy volunteers, 305 sue penetration influence the degree of in knee arthroplasty, 767 Aprepitant fibrinolytic balance alteration following an Angelicae dahuricae evaluation of potential inductive effects of acute myocardial infarction? 150 effects of Corydalis yanhusuo and Angelicae aprepitant on cytochrome P450 3A4 and 2C9 ACE/NEP inhibitor dahuricae cold pressor—induced pain in hu- activity, 215 effect of food on the pharmacokinetics of a dual mans: a controlled trial, 1323 Argatroban angiotensin-converting enzyme/neutral Angiotensin II endopeptidase inhibitor, M100240, 1380 pharmacokinetics and pharmacodynamics of pharmacological and clinical profile of argatroban in combination with a platelet no clinically relevant CYP3A induction with the moexipril: a concise review, 827 glycoprotein IIB/IIIA receptor antagonist in dual angiotensin-converting enzyme/neutral Angiotensin II type 1 receptor patients undergoing percutaneous coronary endopeptidase inhibitor, M100240, 379 rheumatoid arthritis does not reduce the intervention, 981 Adolescents pharmacodynamic response to valsartan, 245 Aripiprazole pharmacokinetics of frovatriptan in adolescent Anidulafungin pharmacokinetics, tolerability, and safety of migraineurs, 1158 population pharmacokinetic analysis of aripiprazole following multiple oral dosing Adverse effects anidulafungin, an echinocandin antifungal, in normal healthy volunteers, 179 hand-foot syndrome in patients treated with 590 Arthritis capecitabine-containing combination che- Anti-inflammatory drugs assessment of visual analog versus categorical motherapy, 1166 analgesic effect of sustained-release flurbiprofen scale for measurement of osteoarthritis pain, intramuscular haloperidol or lorazepam and QT administered at the site of tissue injury in the 368 intervals in schizophrenia, 1173 oral surgery model, 1419 pharmacokinetics of meloxicam in patients with Alcohol Antibacterial juvenile rheumatoid arthritis, 866 the pharmacokinetics and pharmacodynamics of effects of a new antibacterial, telavancin, on car- Arthroplasty ximelagatran, an oral direct thrombin inhibi- diac repolarization (QTc interval duration) in efficacy of oxymorphone extended release in tor, are unaffected by a single dose of alcohol, healthy subjects, 689 postsurgical pain: a randomized clinical trial 388 Anticoagulants in knee arthroplasty, 767 Aldehyde oxidase the pharmacokinetics and pharmacodynamics of Articane hydrochloride human liver aldehyde oxidase: inhibition by 239 ximelagatran, an oral direct thrombin inhibi- pharmacokinetics of articane hydrochloride in drugs, 7 tor, are unaffected by a single dose of alcohol, tumescent local anesthesia for liposuction, Alzheimer’s disease 388 1282 the effects of Ginkgo biloba extracts on the possible induction of cholinesterase in epileptic Aspirin pharmacokinetics and pharmacodynamics of patients treated with anticonvulsant drugs: meloxicam does not affect the antiplatelet effect donepezil, 538 relationship with lipoprotein levels, 974 of aspirin in healthy male and female volun- American College of Clinical Pharmacology safety, tolerability, and pharmacokinetic profile teers, 777 annual meeting abstract, 1185 of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans, 906 1432 ¢ J Clin Pharmacol 2004;44:1432-1442 Asthma Breastfeeding Chiral pharmacokinetics of montelukast in asthmatic characterization of the penetration of role of stereoselective assays in bioequivalence patients 6 to 24 months old, 487 garenoxacin into the breast milk of lactating studies of racemic drugs: have we reached a the pharmacokinetics of nebulized nanocrystal women, 188 consensus? 115 budesonide suspension in healthy volun- BSM-207940 Cholinesterase teers, 6 simulation of the impact of atropisomer possible induction of cholinesterase in epileptic pharmacokinetics, safety, and tolerability of interconversion on plasma exposure of patients treated with anticonvulsant drugs: R411, a dual 0481-0487 integrin antagonist atropisomers of an endothelin receptor antag- relationship with lipoprotein levels, 974 after oral administration at single and multi- onist, 680 Chronic obstructive pulmonary disease ple once-daily ascending doses in healthy Caffeine pharmacokinetics of intravenous, single-dose volunteers, 1369 comparison of various urine collection intervals tiotropium in subjects with different degrees risk-benefit value of inhaled glucocorticoids: a for caffeine and dextromethorphan of renal impairment, 163 pharmacokinetic/pharmacodynamic _per- phenotyping in children, 708 Cilomilast spective, 37 serum metabolite/caffeine ratios as a test for liver lack of pharmacokinetic interactions between Atorvastatin function, 338 cilomilast and theophylline or smoking in no pharmacokinetic or pharmacodynamic inter- Camphor healthy volunteers, 1046 action between atorvastatin and the oral di- dermal absorption of camphor, menthol, and Cimetidine rect thrombin inhibitor ximelagatran, 928 methyl salicylate in humans, 1151 renal interaction between itraconazole and Atropisomer Camptothecin cimetidine, 919 simulation of the impact of atropisomer safety, tolerability, pharmacokinetics, and Ciprofloxacin aitnrtoepricsoonmveerrss ioofn a n oenn dotphlealsimna reecxepptoosru raen tago-f pharmacodynamics of an orally active novel sex-related differences in the pharmacokinetics onist, 680 camptothecin analog, DRF-1042, in refrac- of oral ciprofloxacin, 1012 tory cancer patients in a phase | dose escala- Attention deficit hyperactivity disorder tion study, 723 Cisplatin a single-dose, two-way crossover, bioequivalence Cancer hand-foot syndrome in patients treated with study of dexmethylphenidate HC] with and capecitabine-containing combination che- without food in healthy subjects, 173 pharmacokinetics of gemtuzumab ozogamicin as motherapy, 1166 Azimilide aw istihn glree-fargaecntto ryt reoart mernetl aposfe dp edaicauttrei c mpyaetileonitds Citalopram influence of azimilide on CYP2C19-mediated leukemia, 873 utility of sparse concentration sampling for metabolism, 373 safety, tolerability, pharmacokinetics, and citalopram in elderly clinical trial subjects, Bayes theorem pharmacodynamics of an orally active novel 1353 application of Bayes theorem to aminoglycoside- camptothecin analog, DRF-1042, in refrac- Clinical studies associated nephrotoxicity: comparison of ex- tory cancer patients in a phase I dose escala- application of Bayes theorem to aminoglycoside- tended-interval dosing, individualized tion study, 723 associated nephrotoxicity: comparison of ex- pharmacokinetic monitoring, and multiple- Capecitabine tended-interval dosing, individualized daily dosing, 696 hand-foot syndrome in patients treated with pharmacokinetic monitoring, and multiple- daily dosing, 696 BIA 2-093 capecitabine-containing combination che- safety, tolerability, and pharmacokinetic profile motherapy, 1166 effects of nicotine on the number and activity of circulating endothelial progenitor cells, 881 of BIA 2-093, a novel putative antiepileptic, Cardiac repolarization in a rising multiple-dose study in young effects of an ew antibacterial, telavancin, on car- possible induction of cholinesterase in epileptic healthy humans, 906 diac repolarization (QTc interval duration) in praetliaetnitosn shtirpe atweidt h wiltihp oparnottiecionn vluelvselasn,t 97d4r ugs: Bioavailability healthy subjects, 689 questioning a class effect: does ACE inhibitor tis- absolute bioavailability of imatinib (Glivec ) Cardiovascular disease sue penetration influence the degree of orally versus intravenous infusion, 158 benefits of individualized counseling by the fibrinolytic balance alteration following an influence of omeprazole on bioavailability of bis- pharmacist on the treatment outcomes of acute myocardial infarction? 150 muth following administration of a triple hyperlipidemia in Hong Kong, 632 Clinical trials capsule of bismuth _ biskalcitrate, epidemiology of diabetes, 397 metronidazole, and tetracycline, 640 evaluation of methods for improving precision of Cardiovascular function blood pressure measurements in phase I clin- Bioequivalence effect of acute marijuana on cardiovascular func- ical trials, 457 role of stereoselective assays in bioequivalence tion and central nervous system parecoxib sodium, an injectable COX-2-specific studies of racemic drugs: have we reached a pharmacokinetics of | ’O]water: effect in oc- inhibitor, does not affect unfractionated hep- consensus? 115 casional and chronic users, 751 arin-regulated blood coagulation parameters, Bismuth biskalcitrate Cephalexin 474 influence of omeprazole on bioavailability of bis- randomized crossover study investigating the in- Clofarabine muth following administration of a triple fluence of ranitidine or omeprazole on the population pharmacokinetics of clofarabine, a capsule of bismuth _biskalcitrate, pharmacokinetics of cephalexin second-generation nucleoside analog, in pe- metronidazole, and tetracycline, 640 monohydrate, 1392 diatric patients with acute leukemia, 1309 Blood pressure measurements Cetirizine Clozapine evaluation of methods for improving precision of central effects of fexofenadine and cetirizine: the differential effects of steady-state blood pressure measurements in phase I clin- measurement of psychomotor performance, fluvoxamine on the pharmacokinetics of ical trials, 457 subjective sleepiness, and brain histamine olanzapine and clozapine in healthy volun- Breast cancer H -receptor occupancy using "'C-doxepin teers, 785 lack of attenuation in the antitumor effect of positron emission tomography, 890 teaching application of clinical pharmacology tamoxifen by chronic CYP isoform inhibi- skills using unusual observations from tion, 861 clozapine overdoses, 141 “Cocktail” CYP2C19 Dexmethylphenidate HCl “cocktail” approaches and strategies in drug de- effects of lansoparole pharmacokinetics in rela- a single-dose, two-way crossover, bioequivalence velopment: valuable tool or flawed science? tion to CYP2C19 genotypes, 1223 study of dexmethylphenidate HCl with and 120 influence of azimilide on CYP2C19-mediated without food in healthy subjects, 173 Colitis metabolism, 373 Dextromethorphan MDR1 mRNA expressions in peripheral blood influence of St. John’s wort on CYP2C19 activity comparison of various urine collection intervals mononuclear cells of patients with ulcerative with respect to genotype, 577 for caffeine and dextromethorphan colitis in relation to glucocorticoid adminis- lack of weight-based dose dependency and phenotyping in children, 708 tration, 481 intraindividual variability of omeprazole for pharmacokinetics of dextromethorphan after sin- Congestive heart failure CYP2C19 phenotyping, 966 gle or multiple dosing in combination with pharmacokinetics and pharmacodynamics of omeprazole as a CYP2C19 marker in Chinese quinidine in extensive and_ poor oral levosimendan and its metabolites in pa- subjects: assessment of its gene-dose effect metabolizers, 1132 tients with severe congestive heart failure: a and intrasubject variability, 582 Dextrorphan dosing interval study, 1143 CYP2D6 pharmacokinetics of dextromethorphan after sin- Contraceptives assessment of in vivo CYP2D6 activity: differen- gle or multiple dosing in combination with concomitant administration of lumiracoxib and a tial sensitivity on commonly used probes to quinidine in extensive and poor triphasic oral contraceptive does not affect urine pH, XXX metabolizers, 1132 contraceptive activity or pharmacokinetic CYP3A Diabetes profile, 646 the effects of modifying in vivo cytochrome P450 blood pressure control and nephroprotection in Coronary artery disease 3A (CYP3A) activity on etoricoxib diabetes, 431 effects of nicotine on the number and activity of pharmacokinetics and of etoricoxib adminis- clinical trials and lipid guidelines for type II dia- circulating endothelial progenitor cells, 881 tration on CYP3A activity, 1125 betes, 423 Corydalis yanhusuo interindividual and intraindividual variability of diabetes mellitus: an imperative for prevention effects of Corydalis yanhusuo and Angelicae the urinary 6B8-hydroxycortisol/cortisol ratio and intense management, 394 dahuricae cold pressor—induced pain in hu- in Chinese subjects: implications of its use for epidemiology of diabetes, 397 mans: a controlled trial, 1323 evaluating CYP3A activity, 1413 intense management of diabetes mellitus: role of COX-1 no clinically relevant CYP3A induction with the glucose control and antiplatelet agents, 414 dual angiotensin-converting enzyme/neutral meloxicam does not affect the antiplatelet effect preventing type II diabetes mellitus, 406 otefe rass,p ir7i7n7 in healthy male and female volun- CYP3eAnd4o peptidase inhibitor, M100240, 379 Digoxin absence of a clinically relevant interaction be- COX-2 evaluation of potential inductive effects of tween etanercept and digoxin, 1244 aprepitant on cytochrome P450 3A4 and 2C9 pharmacokinetics of etoricoxib in patients with activity, 215 no pharmacokinetic or pharmacodynamic inter- renal impairment, 48 action between digoxin and the oral direct COX-2 inhibitor induction of CYP3A4 be efavirenz in primary hu- thrombin inhibitor ximelagatran in healthy lumiracoxib: pharmacokinetic and manadn phheepnaotboacrybtietsa:l , co1m2p7a3r ison with rifampin volunteers, 935 pharmacodynamic profile when CYP3A5 Dihydrouracil coadministered with fluconazole in healthy important role of the dihydrouracil/uracil ratio in subjects, 193 tacrolimus dosing in adult lung transplant pa- marked interpatient variations of tients is related to cytochrome P4503A5 gene parecoxib sodium, an injectable COX-2-specific fluoropyrimidine pharmacokinetics and inhibitor, does not affect unfractionated hep- polymorphism, 135 pharmacodynamics, 1260 arin-regulated blood coagulation parameters, Cytochrome P450 enzymes Docetaxel 474 genetic polymorphisms of cytochrome P450 en- hand-foot syndrome in patients treated with Cyclooxygenase zymes and the effect on interindividual, capecitabine-containing combination che- pharmacokinetic variability in extensive the effects of modifying in vivo cytochrome P450 motherapy, 1166 metabolizers, 447 3A (CYP3A) activity on etoricoxib Donepezil pharmacokinetics and of etoricoxib adminis- Daptomycin the effects of Ginkgo biloba extracts on the tration on CYP3A activity, 1125 moderate liver impairment has no influence on pharmacokinetics and pharmacodynamics of pharmacokinetics of etoricoxib in patients with daptomycin pharmacokinetics, 715 donepezil, 538 renal impairment, 48 single-dose pharmacokinetics of daptomycin in Dopamine CYP young and geriatric volunteers, 612 dopamine-1 receptor agonist: renal effects and its “cocktail” approaches and strategies in drug de- Depression potential role in the management of velopment: valuable tool or flawed science? effects of St. John’s wort (Hypericum perforatum) radiocontrast-induced nephropathy, 1343 120 on tacrolimus pharmacokinetics in healthy DOV 216,303 lack of attenuation in the antitumor effect of volunteers, 89 DOV 216,303, “triple” reuptake inhibitor: safety, tamoxifen by chronic CYP isoform inhibi- utility of sparse concentration sampling for tolerability, and pharmacokinetic profile, tion, 861 citalopram in elderly clinical trial subjects, 1361 CYP2C3 1353 evaluation of potential inductive effects of Dermal patches DRF-1042 aprepitant on cytochrome P450 3A4 and 2C9 dermal absorption of camphor, menthol, and safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally active novel activity, 215 methyl salicylate in humans, 1151 camptothecin analog, DRF-1042, in refrac- limited sampling strategy of S-warfarin concen- Desloratadine tory cancer patients in a phase I dose escala- trations, but not warfarin S/R ratios, accu- pharmacokinetics/pharmacodynamics of tion study, 723 rately predicts S-warfarin AUC during base- desloratadine and fluoxetine in healthy vol- Drug development line and inhibition in CYP2C9 extensive unteers, 1252 metabolizers, 570 drug-drug, drug—dietary supplement, and drug— citrus fruit and other food interactions: what have we learned? 55$ 1434 ¢ J Clin Pharmacol 2004;44:1432-1442 effects of a new antibacterial, telavancin, on car- influence of St. John’s wort on CYP2C19 activity pharmacokinetic variability in extensive diac repolarization (QTc interval duration) in with respect to genotype, 577 metabolizers, 447 healthy subjects, 689 interactions of prednisolone and other human liver aldehyde oxidase: inhibition by 239 role of stereoselective assays in bioequivalence immunosuppressants used in dual treatment drugs, 7 studies of racemic drugs: have we reached a of systemic lupus erythematosus in lympho- influence of azimilide on CYP2C19-mediated consensus? 115 cyte proliferation assays, 1034 metabolism, 373 simulation of the impact of atropisomer lack of interaction between enfuvirtide and interindividual and intraindividual variability of interconversion on plasma exposure of ritonavir or ritonavir-boosted saquinavir in the urinary 6B-hydroxycortisol/cortisol ratio atropisomers of an endothelin receptor antag- HIV-1-infected patients, 793 in Chinese subjects: implicaotf iitso unses f or onist, 680 lack of pharmacokinetic interactions between evaluating CYP3A activity, 1413 Drug-dietary supplement cilomilast and theophylline or smoking in limited sampling strategy of S-warfarin concen- drug-drug, drug—dietary supplement, and drug— healthy volunteers, 1046 trations, but not warfarin S/R ratios, accu- citrus fruit and other food interactions: what lumiracoxib: pharmacokinetic and rately predicts S-warfarin AUC during base- have we learned? 559 pharmacodynamic profile when line and inhibition in CYP2C9 extensive Drug-drug interaction coadministered with fluconazole in healthy metabolizers, 570 “cocktail” approaches and strategies in drug de- subjects, 193 metabolism by n-acetyltransferase 1 in vitro and velopment: valuable tool or flawed science? meloxicam does not affect the antiplatelet effect in healthy volunteers: a prototype for tar- 120 of aspirin in healthy male and female volun- geted inhibition, 1406 drug-drug, drug—dietary supplement, and drug— teers, 777 no Clinically relevant CYP3A induction with the citrus fruit and other food interactions: what metabolism by n-acetyltransferase 1 in vitro and dual angiotensin-converting enzyme/neutral have we learned? 559 in healthy volunteers: a prototype for tar- endopeptidase inhibitor, M100240, 379 lack of interaction between enfuvirtide and geted inhibition, 1406 pharmacookf idenxteromtetihocrphsan after sin- ritonavir or ritonavir-boosted saquinavir in no pharmacokinetic or pharmacodynamic inter- gle or multiple dosing in combination with HIV-1-infected patients, 793 action between atorvastatin and the oral di- quinidine in extensive and poor rect thrombin inhibitor ximelagatran, 928 metabolizers, 1132 no Clinically relevant CYP3A induction with the dual angiotensin-converting enzyme/neutral no pharmacokinetic or pharmacodynamic inter- quinidinaes a probe for the role of P-glycoprotein endopeptidase inhibitor, M100240, 379 action between digoxin and the oral direct in the intestinal absorption and clinical ef- thrombin inhibitor ximelagatran in healthy fects of fentanyl, 224 Drug-herb interactions volunteers, 935 tacrolimus dosing in adult lung transplant pa- the effects of Ginkgo biloba extracts on the parecoxib sodium, an injectable COX-2-specific tients is related to cytochrome P4503A5 gene pharmacokinetics and pharmacodynamics of inhibitor, does not affect unfractionated hep- polymorphism, 135 donepezil, 538 arin-regulated blood coagulation parameters, Drug policy Drug interactions 474 could the WHO model list of essential medicines absence of a pharmacokinetic interaction be- a pharmacokinetic study of the combined admin- do more for the safe and appropriate use of in- tween etanercept and warfarin, 543 istration of amiodarone and ximelagatran, an jections? 1106 concomitant administration of lumiracoxib and a oral direct thrombin inhibitor, 1063 Drug safety triphasic oral contraceptive does not affect the pharmacokinetics and pharmacodynamics of cproonftirlae,c ep64t6i ve activity or pharmacokinetic txoirm, ealraeg autnraafnf,e ctaen d orbayl ad isriencgtl et hdroosem biofn a lcionhhiobli,- pharamraicpoipkrianzeotliec sf,o lltoowlienrga bilmiutlyt,i plaen d orasla fedtoys inogf in normal healthy volunteers, 179 the differential effects of steady-state 388 fluvoxamine on the pharmacokinetics of randomized crossover study investigating the in- pharmacokinetics and safety of solifenacin olanzapine and clozapine in healthy volun- fluence of ranitidine or omeprazole on the succinate in healthy young men, 1023 teers, 785 pharmacokinetics of cephalexin ECG readings dose-dependent alternations in the monohydrate, 1392 measuring the effects of supratherapeutic doses pharmacokinetics of olanzapine during renal interaction between itraconazole and of levofloxacin on healthy volunteers using coadministration of fluvoxamine in patients cimetidine, 919 four methods of QT correction and periodic with schizophrenia, 1386 and continuous ECG recordings, 464 simvastatin does not have a clinically significant effect of St. John’s wort on the pharmacokiuetics pharmacokinetic interaction with fenofibrate Education of theophylline in healthy volunteers, 95 in humans, 1054 benefits of individualized counseling by the the effects of once-daily saquinavir/minidose Drug metabolism pharmacist on the treatment outcomes of ritonavir on the pharmacokinetics of metha- “cocktail” approaches and strategies in drug de- hyperlipidemia in Hong Kong, 632 done, 293 velopment: valuable tool or flawed science? putting clinical pharmacology in context: the use effects of St. John’s wort (Hypericum perforatum) of popular movies, 30 120 on tacrolimus pharmacokinetics in healthy comparison of various urine collection intervals teaching application of clinical pharmacology volunteers, 89 for caffeine and dextromethorphan skills using unusual observations from human liver aldehyde oxidase: inhibition by 239 phenotyping in children, 708 clozapine overdoses, 141 drugs, 7 effect of St. John’s wort on the pharmacokinetics Efavirenz ibandronate: a clinical pharmacological and of theophylline in healthy volunteers, 95 induction of CYP3A4 be efavirenz in primary hu- pharmacokinetic update, 951 the effects of modifying in vivo cytochrome P450 man hepatocytes: comparison with rifampin indinavir and rifabutin drug interactions in 3A (CYP3A) activity on etoricoxib and phenobarbital, 1273 healthy volunteers, 305 pharmacokinetics and of etoricoxib adminis- Electroencephalography influence of azimilide on CYP2C19-mediated tration on CYP3A activity, 1125 kinetics and EEG effects of midazolam during metabolism, 373 evaluation of potential inductive effects of and after 1-minute, 1-hour, and 3-hour intra- influence of omeprazole on bioavailability of bis- aprepitant on cytochrome P450 3A4 and 2C9 venous infusions, 605 muth following administration of a tripie activity, 215 capsule of bismuth _ biskalcitrate, genetic polymorphisms of cytochrome P450 en- metronidazole, and tetracycline, 640 zymes and the effect on interindividual, Endogenous cortisol Extended-interval dosing a single-dose, two-way crossover, bioequivalence intranasal loteprednol etabonate in healthy male application of Bayes theorem to aminoglycoside- study of dexmethylphenidate HCl with and subjects: pharmacokinetics and effects of en- associated nephrotoxicity: comparison of ex- without food in healthy subjects, 173 dogenous cortisol, 510 tended-interval dosing, individualized Fosfluconazole Endothelia progenitor cells pharmacokinetic monitoring, and multiple- pharmacokinetics and safety of fosfluconazole af- effects of nicotine on the number and activity of daily dosing, 696 ter single intravenous bolus injection in circulating endothelial progenitor cells, 881 Fenofibrate healthy male Japanese volunteers, 284 Endothelin receptor simvastatin does not have a clinically significant Frovatriptan pharEmTa co-ksielneecttiicves eannddo tphehlairnm arceocdeyptnoarm iacnsta goofn itshte ipnh ahrummaacnosk,i ne1t0i5c4 interaction with fenofibrate pharmmiagcroakiinneeutrsi,c s 11o5f8 frovatriptan in adolescent SPP301 in healthy human subjects, 59 Fenoldopam FTY720 simulation of the impact of atropisomer dopamine-1 receptor agonist: renal effects and its multiple-dose FTY720: tolerability, interconversion on plasma exposure of potential role in the management of pharmacokinetics, and lymphocyte re- atropisomers of an endothelin receptor antag- radiocontrast-induced nephropathy, 1343 sponses in healthy subjects, 5: onist, 680 Fentanyl Gamma hydroxybutyrate Enfuvirtide quinidine as a probe for the role of P-glycoprotein pharmacokinetics of sodium oxybate oral solu- lack of interaction between enfuvirtide and in the intestinal absorption and clinical ef- tion following acute and chronic administra- ritonavir or ritonavir-boosted saquinavir in fects of fentanyl, 224 tion to narcoleptic patients, 253 HIV-1-infected patients, 793 Fexofenadine Garenoxacin Epilepsy central effects of fexofenadine and cetirizine: characterization of the penetration of lack of a clinically significant effect of measurement of psychomotor performance, garenoxacin into the breast milk of lactating zonisamide on phentyoin steady-state subjective sleepiness, and brain histamine women, 188 pharmacokinetics in patients with epilepsy, H -receptor occupancy using C-doxepin Gastric acid-related diseases 1230 positron emission tomography, 890 pharmacokinetic and pharmacodynamic evalua- oxcarbazepine pharmacokinetics and tolerability 5-HT3 receptor antagonist tion of a novel proton pump inhibitor, in children with inadequately controlled epi- pharmacokinetic and safety evaluation of YH1885, in healthy volunteers, 73 lepsy, 1290 palonosetron, a 5-hydroxytryptamine-3 re- GBD project safety, tolerability, and pharmacokinetic profile ceptor antagonist, in U.S. and Japanese of BIA 2-093, a novel putative antiepileptic, healthy subjects, 520 go lobal burden of disease (GBD) for hepatitisC , 20 in a rising multiple-dose study in young Fluconazole Gemtuzumab ozogamicin healthy humans, 906 lumiracoxib: pharmacokinetic and pharmaco- pharmacokinetics of gemtuzumab ozogamicin as Erythromycin breath test dynamic profile when coadministered with a single-agent treatment of pediatric patients the effects of modifying in vivo cytochrome P450 fluconazole in healthy subjects, 193 with refractory or relapsed acute myeloid leukemia, 873 3A (CYP3A) activity on etoricoxib pharmacokinetics and safety of fosfluconazole af- pharmacokinetics and of etoricoxib adminis- ter single intravenous bolus injection in Genetic polymorphisms tration on CYP3A activity, 1125 healthy male Japanese volunteers, 284 differences in drug pharmacokinetics between Erythropoietin Fluoropyrimidine East Asians and Caucasians and the role of ge- netic polymorphisms, 1083 pharmacokinetic and pharmacodynamic model- important role of the dihydrouracil/uracil ratio in ing of recombinant human erythropoietin af- marked _ interpatient variations of genetic polymorphisms of cytochrome P450 en- ter single and multiple doses in healthy vol- fluoropyrimidine pharmacokinetics and zymes and the effect on interindividual, unteers, 991 pharmacodynamics, 1260 pharmacokinetic variability in extensive Estrogen receptor Fluoxetine metabolizers, 447 Geriatric volunteers lack of attenuation in the antitumor effect of pharmacokinetics/pharmacodynamics of tamoxifen by chronic CYP isoform inhibi- desloratadine and fluoxetine in healthy vol- single-dose pharmacokinetics of daptomycin in tion, 861 unteers, 1252 young and geriatric volunteers, 612 ET -selective endothelin receptor antagonist Flurbiprofen utility of sparse concentration sampling for citalopram in elderly clinical trial subjects, pharmacokinetics and pharmacodynamics of the analgesic effect of sustained-release flurbiprofen ET -selective endothelin receptor antagonist administered at the site of tissue injury in the 1353 SPP301 in healthy human subjects, 59 oral surgery model, 1419 Ginkgo biloba Etanercept Fluvoxamine the effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of absence of a clinically relevant interaction be- the differential effects of steady-state donepezil, 538 tween etanercept and digoxin, 1244 fluvoxamine on the pharmacokinetics of absence of a pharmacokinetic interaction be- olanzapine and clozapine in healthy volun- Glucocorticoid therapy tween etanercept and warfarin, 543 teers, 785 MDR1 mRNA expressions in peripheral blood unaltered etanercept pharmacokinetics with con- dose-dependent alternations in the pharmaco- mononuclear cells of patients with ulcerative current methotrexate in patients with rheu- kinetics of olanzapine during coadministra- colitis in relation to glucocorticoid adminis- matoid athritis, 1235 tion of fluvoxamine in patients with schizo- tration, 481 Etoricoxib phrenia, 1386 Glucocorticoids effects of fluvoxamine on lansoprazole pharmacokinetics and pharmacodynamic re- the effects of modifying in vivo cytochrome P450 pharmacokinetics in relation to CYP2C19 ge- sponse of methylprednisolone in premeno- 3A (CYP3A) activity on etoricoxib notypes, 1223 pausal renal transplant recipients, 1003 pharmacokinetics and of etoricoxib adminis- tration on CYP3A activity, 1125 Food-drug interactions Glucocorticosteroids pharmacokinetics of etoricoxib in patients with effect of food on the pharmacokinetics of a dual intranasal loteprednol etabonate in healthy male renal impairment, 48 angiotensin-converting enzyme/neutral subjects: pharmacokinetics and effects of en- endopeptidase inhibitor, M100240, 1380 dogenous cortisol, 510 1436 e¢ J Clin Pharmacol 2004;44:1432-1442 Glucose control Hypertension Ketolide intense management of diabetes mellitus: role of blood pressure control and nephroprotection in pharmacokinetics and safety of the ketolide glucose control and antiplatelet agents, 414 diabetes, 431 telithromycin in patients with renal impair- Glucose intolerance optimizing dose selection with modeling and ment, 234 preventing type II diabetes mellitus, 406 simulation: application to the vasopeptidase Kidney transplantation Glycoprotein Itb/IIa inhibitor M100240, 621 pharmacokinetic study of mycophenolic acid in glycoprotein IIb/IIIa receptor antagonists and risk pharmacokinetics of M100240 and MDL Korean kidney transplant patients, 743 of bleeding: a single-center experience in 100,173, a dual angiotensin-converting en- Kinetics zyme/neutral endopeptidase inhibitor, in 1020 patients, 1328 kinetics and EEG effects of midazolam during healthy young and elderly volunteers, 901 GnRH and after 1-minute, 1-hour, and 3-hour intra- pharmacokinetics of treprostinil sodium admin- venous infusions, 605 pharmacokinetics and pharmacodynamics of a istered by 28-day chronic continuous subcu- novel depot formulation of abarelix, a gonad- taneous infusion, 503 Knee arthroplasty otropin-releasing hormone (GnRH) antago- efficacy of oxymorphone extended release in pharmacological and clinical profile of nist, in healthy men ages 50 to 75, 495 postsurgical pain: a randomized clinical trial moexipril: a concise review, 827 Haloperidol in knee arthroplasty, 767 Ibandronate intramuscular haloperidol or lorazepam and QT Lansoprazole ibandronate: a clinical pharmacological and intervals in schizophrenia, 1173 pharmacokinetic update, 951 effects of fluvoxamine on lansoprazole Hand-foot syndrome pharmacokinetics in relation to CYP2C19 ge- Ibuprofen hand-foot syndrome in patients treated with notypes, 1223 capecitabine-containing combination che- population pharmacokinetics of ibuprofen enan- Leukemia tiomers in very premature neonates, 1114 motherapy, 1166 pharmacokinetics of gemtuzumab ozogamicin as Imatinib Heparin a single-agent treatment of pediatric patients absolute bioavailability of imatinib (Glivec ) with refractory or relapsed acute myeloid parecoxib sodium, an injectable COX-2-specific orally versus intravenous infusion, 158 leukemia, 873 inhibitor, does not affect unfractionated hep- arin-regulated bleod coagulation parameters, Indinavir population pharmacokinetics of clofarabine, a 474 indinavir and rifabutin drug interactions in second-generation nucleoside analog, in pe- Hepatic function healthy volunteers, 305 diatric patients with acute leukemia, 1309 moderate liver impairment has no influence on Inhaled drugs Levofloxacin daptomycin pharmacokinetics, 715 estimating mass balance for inhaled drugs in hu- measuring the effects of supratherapeutic doses Hepatitis C mans: an example with a VLA-4 antagonist, of levofloxacin on healthy volunteers using IVL745, 348 four methods of QT correction and periodic global burden of disease (GBD) for hepatitisC ,2 0 and continuous ECG recordings, 464 Inhaled glucocorticoids pharmacokinetics and safety of viramidine, a Levosimendan prodrug of ribavirin, in healthy volunteers, risk-benefit value of inhaled glucocorticoids: a 265 pharmacokinetic/pharmacodynamic per- pharmacokinetics and pharmacodynamics of spective, 37 oral levosimendan and its metabolites in pa- Hepatocytes Insulin detemir tients with severe congestive heart failure: a induction of CYP3A4 be efavirenz in primary hu- dosing interval study, 1143 man hepatocytes: comparison with rifampin similarity of insulin detemir pharmacokinetics, Liver and phenobarbital, 1273 safety, and tolerability profiles in healthy Caucasian and Japanese American subjects, moderate liver impairment has no influence on Herb-drug interactions 258 daptomycin pharmacokinetics, 715 effect of St. John’s wort on the pharmacokinetics Interethnic variability serum metabolite/caffeine ratios as a test for liver of theophylline in healthy volunteers, 95 function, 338 Herbal medicine differences in drug pharmacokinetics between East Asians and Caucasianasnd the roolfe ge - Lorazepam the effects of Ginkgo biloba extracts on the netic polymorphisms, 1083 intramuscular haloperidol or lorazepam and QT pharmacokinetics and pharmacodynamics of Interindividual variability intervals in schizophrenia, 1173 donepezil, 538 interindividual and intraindividual variability of Loteprednol etabonate Histamine H1-receptor (H1R) the urinary 6B-hydroxycortisol/cortisol ratio intranasal loteprednol etabonate in healthy male central effects of fexofenadine and cetirizine: in Chinese subjects: implications of its use for subjects: pharmacokinetics and effects of en- measurement of psychomotor performance, evaluating CYP3A activity, 1413 dogenous cortisol, 510 subjective sleepiness, and brain histamine Intestinal absorption Lumiracoxib H -receptor occupancy using "'C-doxepin positron emission tomography, 890 quinidinaes a probe for the role of P-glycoprotein concomitant administration of lumiracoxib and a HIV in the intestinal absorption and clinical ef- triphasic oral contraceptive does not affect fects of fentanyl, 224 contraceptive activity or pharmacokinetic indinavir and rifabutin drug interactions in Irinotecan profile, 646 healthy volunteers, 305 influence of genetic variants in UGT1A1 and lumiracoxib: pharmacokinetic and pharmacokinetic and pharmacodynamic analy- UGT1A9 on the in vivo glucuronidation of pharmacodynamic profile when stihse raofp y aminp rHeInVa-v1i—ri-ncfoenctteadi nicnhgi ldrceonm, bi1n3a0t1i on ItraScNo-n3a8z,o le8 54 csuobajdemcitsn,i st1e9r3 ed with fluconazole in healthy Hyperlipidemia Lupus erythematosus renal interaction between itraconazole and benefits of individualized counseling by the cimetidine, 919 interactions of prednisolone and other pharmacist on the treatment outcomes of immunosuppressants used in dual treatment hyperlipidemia in Hong Kong, 632 Juvenile rheumatoid arthritis of systemic lupus erythematosus in lympho- clinical trials and lipid guidelines for type II dia- pharmacokinetics of meloxicam in patients with cyte proliferation assays, 1034 betes, 423 juvenile rheumatoid arthritis, 866 Lymphocyte proliferation assays Methadone colitis in relation to glucocorticoid adminis- interactions of prednisolone and other the effects of once-daily saquinavir/minidose tration, 481 immunosuppressants used in dual treatment ritonavir on the pharmacokinetics of metha- Montelukast of systemic lupus erythematosus in lympho- done, 293 pharmacokinetics of montelukast in asthmatic cyte proliferation assays, 1034 Methods patients 6 to 24 months old, 487 Lymphocyte response assessment of in vivo CYP2D6 activity: differen- Morbidity multiple-dose FTY720: tolerability, tial sensitivity of commonly used probes to epidemiology of diabetes, 397 pharmacokinetics, and lymphocyte re- urine pH, 1399 Movement disorders sponses in healthy subjects, 532 estimating mass balance for inhaled drugs in hu- single oral dose safety, tolerability, and M100240 mans: an example with a VLA-4 antagonist, pharmacokinetics of PNU-96391 in healthy effect of food on the pharmacokinetics of a dual IVL745, 348 volunteers, 276 angiotensin-converting enzyme/neutral evaluation of methods for improving precision of Movies endopeptidase inhibitor, M100240, 1380 blood pressure measurements in phase I clin- no clinically relevant CYP3A induction with the ical trials, 457 putting clinical pharmacology in context: the use of popular movies, 30 dual angiotensin-converting enzyme/neutral global burden of disease (GBD) for hepatitis C, 20 endopeptidase inhibitor, M100240, 379 limited sampling strategy of S-warfarin concen- Multiple-daily dosing pharmacokinetics of M100240 and MDL trations, but not warfarin S/R ratios, accu- application of Bayes theorem to aminoglycoside- 100,173, a dual angiotensin-converting en- rately predicts S-warfarin AUC during base- associated nephrotoxicity: comparison of ex- zyme/neutral endopeptidase inhibitor, in line and inhibition in CYP2C9 extensive tended-interval dosing, individualized healthy young and elderly volunteers, 901 metabolizers, 570 pharmacokinetic monitoring, and multiple- daily dosing, 696 Marijuana measuring the effects of supratherapeutic doses effect of acute marijuana on cardiovascular func- of levofloxacin on healthy volunteers using myocardial infarction tion and central nervous system four methods of QT correction and periodic questioning a class effect: does ACE inhibitor tis- pharmacokin° etic° s of » |1 5’ O|water: efrfeocte in oc- and continuous ECG recordings, 464 sue penetration influence the degree of casional and chronic users, 751 serum metabolite/caffeine ratios as a test for liver fibrinolytic balance alteration following an Mass balance function, 338 acute myocardial infarction? 150 estimating mass balance for inhaled drugs in hu- Methotrexate Mycophenolate mofetil mans: an example with a VLA-4 antagonist, unaltered etanercept pharmacokinetics with con- pharmacokinetic study of mycophenolic acid in IVL745, 348 current methotrexate in patients with rheu- Korean kidney transplant patients, 743 MDL 100,173 matoid athritis, 1235 N-acetylcystein pharmacokinetics of M100240 and MDL Methyl salicylate preventing contrast nephropathy: what is the best 100,173, a dual angiotensin-converting en- dermal absorption of camphor, menthol, and strategy? A review of the literature, 327 zyme/neutral endopeptidase inhibitor, in methyl salicylate in humans, 1151 Nanobudesonide healthy young and elderly volunteers, 901 Methylprednisolone the pharmacokinetics of nebulized nanocrystal MDR1 pharmacokinetics and pharmacodynamic re- budesonide suspension in healthy volun- tacrolimus dosing in adult lung transplant pa- sponse of methylprednisolone in teers, 67 tients is related to cytochrome P4503A5 gene premenopausal renal transplant recipients, Narcolepsy polymorphism, 135 1003 pharmacokinetics of sodium oxybate oral solu- Medicines Microgravity tion following acute and chronic administra- could the WHO model list of essential medicines physiological, pharmacokinetic, and tion to narcoleptic patients, 253 do more for the safe and appropriate use of in- pharmacodynamic changes in space, 837, NAT1 jections? 1106 pharmacokinetics, and pharmacodynamic metabolism by n-acetyltransferase 1 in vitro and Meloxicam changes in space, 837 in healthy volunteers: a prototype for tar- meloxicam does not affect the antiplatelet effect Midazolam geted inhibition, 1406 of aspirin in healthy male and female volun- evaluation of potential inductive effects of Neonates teers, 777 aprepitant on cytochrome P450 3A4 and 2C9 population pharmacokinetics of ibuprofen enan- pharmacokinetics of meloxicam in patients with activity, 215 tiomers in very premature neonates, 1114 juvenile rheumatoid arthritis, 866 kinetics and EEG effects of midazolam during NEP inhibition Menthol and after 1-minute, 1-hour, and 3-hour intra- effect of food on the pharmacokinetics of a dual venous infusions, 605 dermal absorption of camphor, menthol, and angiotensin-coverting enzyme/neutral methyl salicylate in humans, 1151 no clinically relevant CYP3A induction with the endopeptidase inhibitor, M100240, 1380 Metabolism dual angiotensin-converting enzyme/neutral no clinically relevant CYP3A induction with the endopeptidase inhibitor, M100240, 379 absorption of rivastigmine from different regions dual angiotensin-converting enzyme/neutral of the gastrointestinal tract in humans, 599 Migraine endopeptidase inhibitor, M100240, 379 Metabolizers pharmacokinetics of frovatriptan in adolescent optimizing dose selection with modeling and genetic polymorphisms of cytochrome P450 en- migraineurs, 1158 simulation: application to the vasopeptidase pharmacokinetics of sumatriptan nasal spray in inhibitor M100240, 621 zymes and the effect on interindividual, pharmacokinetic variability in extensive children, 359 Nephropathy metabolizers, 447 Modafinil preventing contrast nephropathy: what is the best pharmacokinetics of dextromethorphan after sin- effect of modafinil on acute pain: a randomized strategy? A review of the literature, 327 gle or multiple dosing in combination with double-blind crossover study, 1426 Neutral endopeptidase (NEP) quinidine in extensive and poor Molecular pharmacology pharmacokinetics of M100240 and MDL metabolizers, 1132 MDR1 mRNA expressions in peripheral blood 100,173, a dual angiotensin-converting en- mononuclear cells of patients with ulcerative zyme/neutral endopeptidase inhibitor, in healthy young and elderly volunteers, 901 1438 ¢ J Clin Pharmacol 2004;44:1432-1442

ebook img

Journal of Clinical Pharmacology 2004: Vol 44 Index PDF

2004·4.8 MB·English
by  
#periodicals #sim_microfilm #pub_journal-of-clinical-pharmacology
Save to my drive
Quick download
Download
Upgrade Premium
Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.

Preview Journal of Clinical Pharmacology 2004: Vol 44 Index

Hariparsad N, 1273 Jusko WJ, 991, 1034 Lasseter KC, 1054 Mayer PR, 873, 1235 Harmatz JS, 605 Juszczyk J, 338 Lau DTW, 495 Mayersohn M, 1151 Hartford A, 487, 1054 Kadota R, 1309 Laurent A, 193 Mazenko RS, 48, 1125 Harvey AT, 1173 Kalbag J, 646 LaVallee N, 510 McCrea JB, 305 Hashem M, 1328 Kalies I, 928 Le Coz F, 1244 McCurry K, 135 Haskell LP, 621 Kamal MA, 1034 Leclerc V, 234 McDade K, 135 Hayes MJ, 158 Kaneda A, 538 Lee D, 767 McLeod JF, 120 He W, 1054 Kaneko S, 538 Lee JS, 1166 Mehendale SR, 1323 Hebert MF, 89 Kang Y-K, 1166 Lee L, 599 Mehring G, 158 Heinpalu M, 1143 Kantesaria B, 1252 Lee SSCL, 632 Menchaca D, 495 Henkel T, 590 Karyekar CS, 919 Lee Y, 215 Metzger D, 543 Heo YS, 1166 Kashuba ADM, 570, 708 Leeder JS, 708 Meverrose GE, 150 Hermann R, 510 Katneni K, 723 Leese P, 646 Michael J, 1328 Hermida J, 974 Kato M, 890 Lefebvre M, 640 Michiels N, 1125 Herron J, 1252 Katzper M, 368 Lehmann D, 861 Mignot A, 1114 Hewitt RG, 293 Kays MB, 1012 Lehtonen L, 1143 Migoya E, 487 Hichwa RD, 751 Kazierad DJ, 457 Leibowitz MT, 258 Miller JL, 1125 Hirano T, 481 Kearns GL, 487 Lensing P, 837 Millerioux L, 1114 Hochhaus G, 510 Keefe DL, 679 Leroy B, 234 Milosavljev S, 193, 646 Hoelscher D, 689 Kennedy MJ, 708 Lesko LJ, 559 Minton N, 991 Hoffer C, 224 Kessler E, 388, 935 Levy RH, 1230 Mivaoka M, 481 Hogerzeil HV, 1106 Khalil MH, 1132 Lew RA, 457 Mochizuki H, 890 Holdbrook F, 981 Kharasch ED, 224 Lewanczuk RZ, 245 Moncrief JW, 48 Holloway K, 1106 Khetani VD, 173 Li Q, 577 Montay G, 234 Hossain M, 599 Kim JS, 570 Li W-B, 785 Moon B-S, 73 Howell SR, 379 Kim K, 1083 Li Z,. 577 Morganroth J, 689 Hu P, 1260 Kim M-J, 570, 696, 966 Lim H-S, 73 Morimoto T, 95 Huang M, 1023 Kim SB, 1166 Lin C-C, 265 Moriyasu F, 481 Huang S-M, 559 Kim SC, 743 Linke R, 866 Moser L, 1328 Hubbard RC, 474 Kim TW, 1166 Liu J, 577 Motte J, 1290 Hughes D, 680 Kim WK, 1166 Liu L, 1054 Mottern RK, 359 Hunt T, 532 Kinchelow T, 793 Ljungqvist A, 293 Mudaliar S, 414 Hunt TL, 83, 503 Kink-Eiband M, 777 Lloyd P, 158 Murdoch RD, 1046 Hutin YJF, 1106 Kirkesseli S, 348 Locher M, 510 Murphy G, 1054 Huynh P, 7 Kitt M, 689 Logez SMD, 1106 Nafziger AN, 447, 570, 696, Iacono A, 135 Kleiman NS, 981 Loogna I, 1143 966 Imai H, 95 Kline WF, 48 Lou Y, 1301 Nakano S, 95 Ishkanian G, 1158 Knebel W, 590 Lowry R, 305 Nallani SC, 1273 Itoh M, 890 Knorr B, 487 Lu J, 1260 Natarajan J, 464 Iwabuchi K, 890 Koeppel J, 751 Ludden T, 590 Nave R, 37 Iwata R, 890 Kolis S, 793 Lyness WH, 258 Nelsen J, 861 Jabbour JT, 359 Korth-Bradley J, 543, 873, 1244 Ma JD, 447, 570 Neumayer H-H, 163 Jacobs L-D, 1282 Kotegawa T, 95 Ma T, 767 Newman N, 861 Jacobsen LV, 258 Kovarik JM, 532 Maglio D, 188 Nicolau DP, 188 Jamali F, 245 Kowey PR, 1063 Majumdar AK, 215 Noel GJ, 464 Jang I-J, 73 Kraft WK, 67, 305, 1125 Mallikaarjun S, 179 Noveck RJ, 474 Jeha S, 1309 Krause D, 590 Mamidi RNVS, 723 Obach RS, 7 Jenkins PL, 696 Krauwinkel WJ, 1023 Mann J, 59 Oertel R, 1282 Jensen BK, 348, 901 Kuritsch I, 777 Marbury T, 234 Oh JM, 743 Jhee SS, 258 Kusma SE, 305 Marbury TC, 48 Ohlsson L, 928 Jiang H, 1260 Kutz K, 59 Markabi S, 1290 Ohtani Y, 95 Jiang J, 1260 Kuzmak B, 373 Martin D, 1151 Oka K, 481 Jiang T, 1323 Lai A, 253 Martin LL, 379, 901 Okerholm RA, 253 Jiwatani S, 723 Lai AA, 83, 503 Martin NE, 379, 621, 901 O'Leary DS, 751 Jodynis-Liebert J, 338 LaLonde T, 1328 Massicotte J, 640 Onda K, 481 Johansson S, 388 Lam GN, 1309 Mathijssen RHJ, 854 Overholser BR, 1012 Johnson JA, 1083 Lamba J, 135 Matthews CZ, 48, 1125 Padmanabhan M, 464 Johnson M, 1301 Larson AM, 89 Matuszewska A, 338 Pairet M, 777 Palic B, 293 Roze J-C, 1114 Solanki B, 464 Valesky R, 1054 Pan W-], 1230 Russell A, 245 Song K-S, 73 van Adelsberg J, 487 Paolini JF, 1054 Russo R, 188 Sowers JR, 397 van Ryn J, 777 Paoluzzi L, 854 Ruxrungtham K, 793 Sowinski KM, 1012 Vargas R, 234 Parchman LG, 981 Rytting M, 1309 Sparreboom A, 854 Vega JM, 1054 Parisi S, 520 Ryu M-H, 1166 Spénard J, 640 Venkataramanan R, 743 Park JM, 89 Sack M, 234 Spencer E, 689 Venuto RC, 1003 Parks V, 543, 1244 Sack MR, 48 Srinivas ML, 723 Verweij J, 854 Patat A, 543, 1244 Saito M, 1223 Srinivas NR, 115, 723 von Moltke LL, 679 Patel IH, 793 Sakurada Y, 890 Staton BA, 276 Wacholtz MC, 991 Peng B, 158 Salazar DE, 179 Steiger B, 67 Wade A, 1158 Petty KJ, 48, 215 Sane RS, 1273 Stein DS, 1301 Wade M, 83, 503 Pfister M, 621 Sarich TC, 388, 935, 1063 Steinherz P, 1309 Wajdula J, 1235 Philips L, 265 Sarich TS, 928 Stiles M, 1132 Waldman SA, 67, 305, Pistner H, 1282 Sattler G, 1282 Stirling DI, 173 Wall U, 388, 928, 935 Planken U, 1143 Scavone JM, 605 Stogniew M, 590 Wallenstein G, 777 Plunkett W, 1309 Scharf MB, 253 Stoltz R, 520 Wang C-Y, 785, 1323 Poder P, 1143 Scheffler MR, 173 Sturm Y, 1290 Wang D, 577 Pokorny R, 158 Schinzel S, 1282 Stypinski D, 173 Wang L-S, 577 Pollak PT, 141 Schmerler M, 1230 Suarez JA, 150 Wang X, 881 Pons G, 1290 Schmitt BA, 751 Subramaniam S, 723 Wang Y, 532, 599, 646 Ponto LLB, 751 Schmouder R, 532 Sugawara K, 1223 Ward CA, 751 Pope LE, 1132 Schofield JP, 1046 Sundberg S, 1143 Watkins GL, 751 Porras AG, 48, 1125 Schreiber TL, 1328 Surath A, 723 Waye MMY, 582 Preskorn SH, 1173 Schuck EL, 837 Swan S, 48 Webber DM, 1046 Price DK, 854 Schuetz E, 135 Swan SK, 234 Webber S, 135 Prisant LM, 394, 406, 423 Schultz A, 1125 Swart PJ, 1023 Weber W, 163 Prueksaritanont T, 1054 Schur JL, 293 Szefler S, 37 Wehling M, 1125 Putcha L, 837 Schiitzer K-M, 388, 928, 935, 1063 Takahata T, 1223 Wei GC, 457 Qiu Y, 1054 Schwartz JI, 48 Tan K, 284 Weitman S, 1309 Quiring JN, 67 Scott G, 193, 646 Tang ZR, 577 Weng Y-Z, 785 Ragueneau-Majlessi I, 1230 Sedek G, 599 Tashiro M, 890 Werder S, 1173 Rajman I, 457 Seiberling M, 158 Tateishi T, 538, 1223 Whitaker A-M, 188 Ramakrishnan R, 991 Sekiguchi K, 284 Tay LK, 680 Whittington D, 224 Ramananth V, 861 Sellers EM, 966, 1132 Teng R, 388, 1063 Winchell GA, 305 Randall S, 1301 Shader RI, 605 Teo SK, 173 Winer N, 397 Rantanen S, 1143 Shadle CR, 215 Terra SG, 457 Wollbratt M, 935 Razzouk B, 1309 Shafer SL, 141 Thomas SD, 173 Wong DF, 890 Reed KA, 1003 Shah A, 520 Thompson GA, 373 Wong PH, 48 Reed RC, 737 Shah B, 348 Thon A, 866 Wong SL, 495 Rehan A, 1328 Shah J, 1230 Toma T, 481 Woolf EJ, 48, 305, 1125 Rey E, 1290 Shang Y, 881 Tomlinson B, 582 Worley DJ, 373 Richmond JCW, 751 Shelton MJ, 293 Tong Z, 120 Worth E, 951 Richter K, 1282 Shi J, 234 Tornatore KM, 1003 Wu A, 173 Ristich J, 135 Shimatani K, 284 Tozzi CA, 487 Wu J, 577 Riviere G-J, 532 Shin S-G, 73 Tran A, 1290 Xu C, 265 Robson RA, 48 Shon J-H, 73 Tremblay C, 640 Yakatan GJ, 1132 Rodriguez CA, 276 Shoyama Y, 1323 Trummlitz G, 777 Yamasaki H, 1328 Rohatagi S, 37, 348 Siebert-Weigel M, 510 Tsikouris JP, 150, 327 Yanai K, 890 Rojas PB, 258 Sigmund R, 163 Tsutsumi K, 95 Yasui-Furukori N, 538, 1223 Romanelli M, 1328 Simcoe D, 1244 Tuerck D, 866 Yeh C-M, 193 Rominger K-L, 163 Singh AS, 854 Tiirck D, 163 Yeh L-T, 265 RordorfC , 193, 646 Slowinski T, 163 Tutor JC, 974 ¥i:S-¥773 Roscigno R, 83, 503 Smith A, 861 Tutor-Crespo MJ, 974 Yih L, 193 Rosenfeld W, 1230 Smith J, 150 Uno' Tt, 1223 Yin OQP, 582 Roset PN, 30 Smulders RA, 1023 Uppalapati S, 723 Yu K-S, 73 Rosman HS, 1328 Soares-da-Silva P, 906 Upreti VV, 723 Yuan C-S, 1323 Rowland E, 570 Sobue S, 284 Jaldez J, 1151 Zaldonis D, 135 Zarotsky V, 258 Zhang X, 793 Zheng H, 135 Zhu J, 881 Zech K, 37 Zhang Y, 966 Zhou G, 577 Zhu R-H, 785 Zeevi A, 135 Zhang Z-J, 785 Zhou H, 120, 543, 1235, 1244 Ziska M, 150 Zeng Z, 348 Zhao J, 487 Zhou H-H, 577, 785 Zussman B, 1046 Zhai Y-M, 785 Zhao JJ, 1054 Zhou YS, 680 Zhang J, 135, 348 Zhao J-P, 785 Zhu B, 577 Subject Index, Volume 44 (2004) Abarelix Aminoglycoside-associated nephrotoxicity Antidepressives pharmacokinetics and pharmacodynamics of a application of Bayes theorem to aminoglycoside- DOV 216,303, “triple” reuptake inhibitor: safety, novel depot formulation of abarelix, a gonad- associated nephrotoxicity: comparison of ex- tolerability, and pharmacokinetic profile, otropin-releasing hormone (GnRH) antago- tended-interval dosing, individualized 1361 nist, in healthy men ages 50 to 75, 495 pharmacokinetic monitoring, and multiple- Antiemetic agents Absolute bioavailability daily dosing, 696 pharmacokinetic and safety evaluation of absolute bioavailability and pharmacokinetics of Amiodarone palonosetron, a 5-hydroxytryptamine-3 re- treprostinil sodium administered by acute a pharmacokinetic study of the combined admin- ceptor antagonist, in U.S. and Japanese subcutaneous infusion, 83 istration of amiodarone and ximelagatran, an healthy subjects, 520 Absorption oral direct thrombin inhibitor, 1063 Antifungal absorption of rivastigmine from different regions Amprenavir pharmacokinetics and safety of fosfluconazole af- of the gastrointestinal tract in humans, pharmacokinetic and pharmacodynamic analy- ter single intravenous bolus injection in ACE inhibitor sis of amprenavir-containing combination healthy male Japanese volunteers, 284 blood pressure control and nephroprotection in therapy in HIV-1-infected children, 1301 population pharmacokinetic analysis of diabetes, 431 Analgesia anidulafungin, an echinocandin antifungal, optimizing dose selection with modeling and analgesic effect of sustained-release flurbiprofen 590 simulation: application to the vasopeptidase administered at the site of tissue injury in the Antiplatelet inhibitor M100240, 621 oral surgery model, 1419 intense management of diabetes mellitus: role of pharmacokinetics of M100240 and MDL assessment of visual analog versus categorical glucose control and antiplatelet agents, 414 100,173, a dual angiotensin-converting en- scale for measurement of osteoarthritis pain, meloxicam does not affect the antiplatelet effect zyme/neutral endopeptidase inhibitor, in 368 of aspirin in healthy male and female volun- healthy young and elderly volunteers, 901 effect of modafinil on acute pain: a randomized teers, 777 pharmacological and clinical profile of double-blind crossover study, 1426 Antiretrovirals moexipril: a concise review, 827 efficacy of oxymorphone extended release in indinavir and rifabutin drug interactions in questioning a class effect: does ACE inhibitor tis- postsurgical pain: a randomized clinical trial healthy volunteers, 305 sue penetration influence the degree of in knee arthroplasty, 767 Aprepitant fibrinolytic balance alteration following an Angelicae dahuricae evaluation of potential inductive effects of acute myocardial infarction? 150 effects of Corydalis yanhusuo and Angelicae aprepitant on cytochrome P450 3A4 and 2C9 ACE/NEP inhibitor dahuricae cold pressor—induced pain in hu- activity, 215 effect of food on the pharmacokinetics of a dual mans: a controlled trial, 1323 Argatroban angiotensin-converting enzyme/neutral Angiotensin II endopeptidase inhibitor, M100240, 1380 pharmacokinetics and pharmacodynamics of pharmacological and clinical profile of argatroban in combination with a platelet no clinically relevant CYP3A induction with the moexipril: a concise review, 827 glycoprotein IIB/IIIA receptor antagonist in dual angiotensin-converting enzyme/neutral Angiotensin II type 1 receptor patients undergoing percutaneous coronary endopeptidase inhibitor, M100240, 379 rheumatoid arthritis does not reduce the intervention, 981 Adolescents pharmacodynamic response to valsartan, 245 Aripiprazole pharmacokinetics of frovatriptan in adolescent Anidulafungin pharmacokinetics, tolerability, and safety of migraineurs, 1158 population pharmacokinetic analysis of aripiprazole following multiple oral dosing Adverse effects anidulafungin, an echinocandin antifungal, in normal healthy volunteers, 179 hand-foot syndrome in patients treated with 590 Arthritis capecitabine-containing combination che- Anti-inflammatory drugs assessment of visual analog versus categorical motherapy, 1166 analgesic effect of sustained-release flurbiprofen scale for measurement of osteoarthritis pain, intramuscular haloperidol or lorazepam and QT administered at the site of tissue injury in the 368 intervals in schizophrenia, 1173 oral surgery model, 1419 pharmacokinetics of meloxicam in patients with Alcohol Antibacterial juvenile rheumatoid arthritis, 866 the pharmacokinetics and pharmacodynamics of effects of a new antibacterial, telavancin, on car- Arthroplasty ximelagatran, an oral direct thrombin inhibi- diac repolarization (QTc interval duration) in efficacy of oxymorphone extended release in tor, are unaffected by a single dose of alcohol, healthy subjects, 689 postsurgical pain: a randomized clinical trial 388 Anticoagulants in knee arthroplasty, 767 Aldehyde oxidase the pharmacokinetics and pharmacodynamics of Articane hydrochloride human liver aldehyde oxidase: inhibition by 239 ximelagatran, an oral direct thrombin inhibi- pharmacokinetics of articane hydrochloride in drugs, 7 tor, are unaffected by a single dose of alcohol, tumescent local anesthesia for liposuction, Alzheimer’s disease 388 1282 the effects of Ginkgo biloba extracts on the possible induction of cholinesterase in epileptic Aspirin pharmacokinetics and pharmacodynamics of patients treated with anticonvulsant drugs: meloxicam does not affect the antiplatelet effect donepezil, 538 relationship with lipoprotein levels, 974 of aspirin in healthy male and female volun- American College of Clinical Pharmacology safety, tolerability, and pharmacokinetic profile teers, 777 annual meeting abstract, 1185 of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans, 906 1432 ¢ J Clin Pharmacol 2004;44:1432-1442 Asthma Breastfeeding Chiral pharmacokinetics of montelukast in asthmatic characterization of the penetration of role of stereoselective assays in bioequivalence patients 6 to 24 months old, 487 garenoxacin into the breast milk of lactating studies of racemic drugs: have we reached a the pharmacokinetics of nebulized nanocrystal women, 188 consensus? 115 budesonide suspension in healthy volun- BSM-207940 Cholinesterase teers, 6 simulation of the impact of atropisomer possible induction of cholinesterase in epileptic pharmacokinetics, safety, and tolerability of interconversion on plasma exposure of patients treated with anticonvulsant drugs: R411, a dual 0481-0487 integrin antagonist atropisomers of an endothelin receptor antag- relationship with lipoprotein levels, 974 after oral administration at single and multi- onist, 680 Chronic obstructive pulmonary disease ple once-daily ascending doses in healthy Caffeine pharmacokinetics of intravenous, single-dose volunteers, 1369 comparison of various urine collection intervals tiotropium in subjects with different degrees risk-benefit value of inhaled glucocorticoids: a for caffeine and dextromethorphan of renal impairment, 163 pharmacokinetic/pharmacodynamic _per- phenotyping in children, 708 Cilomilast spective, 37 serum metabolite/caffeine ratios as a test for liver lack of pharmacokinetic interactions between Atorvastatin function, 338 cilomilast and theophylline or smoking in no pharmacokinetic or pharmacodynamic inter- Camphor healthy volunteers, 1046 action between atorvastatin and the oral di- dermal absorption of camphor, menthol, and Cimetidine rect thrombin inhibitor ximelagatran, 928 methyl salicylate in humans, 1151 renal interaction between itraconazole and Atropisomer Camptothecin cimetidine, 919 simulation of the impact of atropisomer safety, tolerability, pharmacokinetics, and Ciprofloxacin aitnrtoepricsoonmveerrss ioofn a n oenn dotphlealsimna reecxepptoosru raen tago-f pharmacodynamics of an orally active novel sex-related differences in the pharmacokinetics onist, 680 camptothecin analog, DRF-1042, in refrac- of oral ciprofloxacin, 1012 tory cancer patients in a phase | dose escala- Attention deficit hyperactivity disorder tion study, 723 Cisplatin a single-dose, two-way crossover, bioequivalence Cancer hand-foot syndrome in patients treated with study of dexmethylphenidate HC] with and capecitabine-containing combination che- without food in healthy subjects, 173 pharmacokinetics of gemtuzumab ozogamicin as motherapy, 1166 Azimilide aw istihn glree-fargaecntto ryt reoart mernetl aposfe dp edaicauttrei c mpyaetileonitds Citalopram influence of azimilide on CYP2C19-mediated leukemia, 873 utility of sparse concentration sampling for metabolism, 373 safety, tolerability, pharmacokinetics, and citalopram in elderly clinical trial subjects, Bayes theorem pharmacodynamics of an orally active novel 1353 application of Bayes theorem to aminoglycoside- camptothecin analog, DRF-1042, in refrac- Clinical studies associated nephrotoxicity: comparison of ex- tory cancer patients in a phase I dose escala- application of Bayes theorem to aminoglycoside- tended-interval dosing, individualized tion study, 723 associated nephrotoxicity: comparison of ex- pharmacokinetic monitoring, and multiple- Capecitabine tended-interval dosing, individualized daily dosing, 696 hand-foot syndrome in patients treated with pharmacokinetic monitoring, and multiple- daily dosing, 696 BIA 2-093 capecitabine-containing combination che- safety, tolerability, and pharmacokinetic profile motherapy, 1166 effects of nicotine on the number and activity of circulating endothelial progenitor cells, 881 of BIA 2-093, a novel putative antiepileptic, Cardiac repolarization in a rising multiple-dose study in young effects of an ew antibacterial, telavancin, on car- possible induction of cholinesterase in epileptic healthy humans, 906 diac repolarization (QTc interval duration) in praetliaetnitosn shtirpe atweidt h wiltihp oparnottiecionn vluelvselasn,t 97d4r ugs: Bioavailability healthy subjects, 689 questioning a class effect: does ACE inhibitor tis- absolute bioavailability of imatinib (Glivec ) Cardiovascular disease sue penetration influence the degree of orally versus intravenous infusion, 158 benefits of individualized counseling by the fibrinolytic balance alteration following an influence of omeprazole on bioavailability of bis- pharmacist on the treatment outcomes of acute myocardial infarction? 150 muth following administration of a triple hyperlipidemia in Hong Kong, 632 Clinical trials capsule of bismuth _ biskalcitrate, epidemiology of diabetes, 397 metronidazole, and tetracycline, 640 evaluation of methods for improving precision of Cardiovascular function blood pressure measurements in phase I clin- Bioequivalence effect of acute marijuana on cardiovascular func- ical trials, 457 role of stereoselective assays in bioequivalence tion and central nervous system parecoxib sodium, an injectable COX-2-specific studies of racemic drugs: have we reached a pharmacokinetics of | ’O]water: effect in oc- inhibitor, does not affect unfractionated hep- consensus? 115 casional and chronic users, 751 arin-regulated blood coagulation parameters, Bismuth biskalcitrate Cephalexin 474 influence of omeprazole on bioavailability of bis- randomized crossover study investigating the in- Clofarabine muth following administration of a triple fluence of ranitidine or omeprazole on the population pharmacokinetics of clofarabine, a capsule of bismuth _biskalcitrate, pharmacokinetics of cephalexin second-generation nucleoside analog, in pe- metronidazole, and tetracycline, 640 monohydrate, 1392 diatric patients with acute leukemia, 1309 Blood pressure measurements Cetirizine Clozapine evaluation of methods for improving precision of central effects of fexofenadine and cetirizine: the differential effects of steady-state blood pressure measurements in phase I clin- measurement of psychomotor performance, fluvoxamine on the pharmacokinetics of ical trials, 457 subjective sleepiness, and brain histamine olanzapine and clozapine in healthy volun- Breast cancer H -receptor occupancy using "'C-doxepin teers, 785 lack of attenuation in the antitumor effect of positron emission tomography, 890 teaching application of clinical pharmacology tamoxifen by chronic CYP isoform inhibi- skills using unusual observations from tion, 861 clozapine overdoses, 141 “Cocktail” CYP2C19 Dexmethylphenidate HCl “cocktail” approaches and strategies in drug de- effects of lansoparole pharmacokinetics in rela- a single-dose, two-way crossover, bioequivalence velopment: valuable tool or flawed science? tion to CYP2C19 genotypes, 1223 study of dexmethylphenidate HCl with and 120 influence of azimilide on CYP2C19-mediated without food in healthy subjects, 173 Colitis metabolism, 373 Dextromethorphan MDR1 mRNA expressions in peripheral blood influence of St. John’s wort on CYP2C19 activity comparison of various urine collection intervals mononuclear cells of patients with ulcerative with respect to genotype, 577 for caffeine and dextromethorphan colitis in relation to glucocorticoid adminis- lack of weight-based dose dependency and phenotyping in children, 708 tration, 481 intraindividual variability of omeprazole for pharmacokinetics of dextromethorphan after sin- Congestive heart failure CYP2C19 phenotyping, 966 gle or multiple dosing in combination with pharmacokinetics and pharmacodynamics of omeprazole as a CYP2C19 marker in Chinese quinidine in extensive and_ poor oral levosimendan and its metabolites in pa- subjects: assessment of its gene-dose effect metabolizers, 1132 tients with severe congestive heart failure: a and intrasubject variability, 582 Dextrorphan dosing interval study, 1143 CYP2D6 pharmacokinetics of dextromethorphan after sin- Contraceptives assessment of in vivo CYP2D6 activity: differen- gle or multiple dosing in combination with concomitant administration of lumiracoxib and a tial sensitivity on commonly used probes to quinidine in extensive and poor triphasic oral contraceptive does not affect urine pH, XXX metabolizers, 1132 contraceptive activity or pharmacokinetic CYP3A Diabetes profile, 646 the effects of modifying in vivo cytochrome P450 blood pressure control and nephroprotection in Coronary artery disease 3A (CYP3A) activity on etoricoxib diabetes, 431 effects of nicotine on the number and activity of pharmacokinetics and of etoricoxib adminis- clinical trials and lipid guidelines for type II dia- circulating endothelial progenitor cells, 881 tration on CYP3A activity, 1125 betes, 423 Corydalis yanhusuo interindividual and intraindividual variability of diabetes mellitus: an imperative for prevention effects of Corydalis yanhusuo and Angelicae the urinary 6B8-hydroxycortisol/cortisol ratio and intense management, 394 dahuricae cold pressor—induced pain in hu- in Chinese subjects: implications of its use for epidemiology of diabetes, 397 mans: a controlled trial, 1323 evaluating CYP3A activity, 1413 intense management of diabetes mellitus: role of COX-1 no clinically relevant CYP3A induction with the glucose control and antiplatelet agents, 414 dual angiotensin-converting enzyme/neutral meloxicam does not affect the antiplatelet effect preventing type II diabetes mellitus, 406 otefe rass,p ir7i7n7 in healthy male and female volun- CYP3eAnd4o peptidase inhibitor, M100240, 379 Digoxin absence of a clinically relevant interaction be- COX-2 evaluation of potential inductive effects of tween etanercept and digoxin, 1244 aprepitant on cytochrome P450 3A4 and 2C9 pharmacokinetics of etoricoxib in patients with activity, 215 no pharmacokinetic or pharmacodynamic inter- renal impairment, 48 action between digoxin and the oral direct COX-2 inhibitor induction of CYP3A4 be efavirenz in primary hu- thrombin inhibitor ximelagatran in healthy lumiracoxib: pharmacokinetic and manadn phheepnaotboacrybtietsa:l , co1m2p7a3r ison with rifampin volunteers, 935 pharmacodynamic profile when CYP3A5 Dihydrouracil coadministered with fluconazole in healthy important role of the dihydrouracil/uracil ratio in subjects, 193 tacrolimus dosing in adult lung transplant pa- marked interpatient variations of tients is related to cytochrome P4503A5 gene parecoxib sodium, an injectable COX-2-specific fluoropyrimidine pharmacokinetics and inhibitor, does not affect unfractionated hep- polymorphism, 135 pharmacodynamics, 1260 arin-regulated blood coagulation parameters, Cytochrome P450 enzymes Docetaxel 474 genetic polymorphisms of cytochrome P450 en- hand-foot syndrome in patients treated with Cyclooxygenase zymes and the effect on interindividual, capecitabine-containing combination che- pharmacokinetic variability in extensive the effects of modifying in vivo cytochrome P450 motherapy, 1166 metabolizers, 447 3A (CYP3A) activity on etoricoxib Donepezil pharmacokinetics and of etoricoxib adminis- Daptomycin the effects of Ginkgo biloba extracts on the tration on CYP3A activity, 1125 moderate liver impairment has no influence on pharmacokinetics and pharmacodynamics of pharmacokinetics of etoricoxib in patients with daptomycin pharmacokinetics, 715 donepezil, 538 renal impairment, 48 single-dose pharmacokinetics of daptomycin in Dopamine CYP young and geriatric volunteers, 612 dopamine-1 receptor agonist: renal effects and its “cocktail” approaches and strategies in drug de- Depression potential role in the management of velopment: valuable tool or flawed science? effects of St. John’s wort (Hypericum perforatum) radiocontrast-induced nephropathy, 1343 120 on tacrolimus pharmacokinetics in healthy DOV 216,303 lack of attenuation in the antitumor effect of volunteers, 89 DOV 216,303, “triple” reuptake inhibitor: safety, tamoxifen by chronic CYP isoform inhibi- utility of sparse concentration sampling for tolerability, and pharmacokinetic profile, tion, 861 citalopram in elderly clinical trial subjects, 1361 CYP2C3 1353 evaluation of potential inductive effects of Dermal patches DRF-1042 aprepitant on cytochrome P450 3A4 and 2C9 dermal absorption of camphor, menthol, and safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally active novel activity, 215 methyl salicylate in humans, 1151 camptothecin analog, DRF-1042, in refrac- limited sampling strategy of S-warfarin concen- Desloratadine tory cancer patients in a phase I dose escala- trations, but not warfarin S/R ratios, accu- pharmacokinetics/pharmacodynamics of tion study, 723 rately predicts S-warfarin AUC during base- desloratadine and fluoxetine in healthy vol- Drug development line and inhibition in CYP2C9 extensive unteers, 1252 metabolizers, 570 drug-drug, drug—dietary supplement, and drug— citrus fruit and other food interactions: what have we learned? 55$ 1434 ¢ J Clin Pharmacol 2004;44:1432-1442 effects of a new antibacterial, telavancin, on car- influence of St. John’s wort on CYP2C19 activity pharmacokinetic variability in extensive diac repolarization (QTc interval duration) in with respect to genotype, 577 metabolizers, 447 healthy subjects, 689 interactions of prednisolone and other human liver aldehyde oxidase: inhibition by 239 role of stereoselective assays in bioequivalence immunosuppressants used in dual treatment drugs, 7 studies of racemic drugs: have we reached a of systemic lupus erythematosus in lympho- influence of azimilide on CYP2C19-mediated consensus? 115 cyte proliferation assays, 1034 metabolism, 373 simulation of the impact of atropisomer lack of interaction between enfuvirtide and interindividual and intraindividual variability of interconversion on plasma exposure of ritonavir or ritonavir-boosted saquinavir in the urinary 6B-hydroxycortisol/cortisol ratio atropisomers of an endothelin receptor antag- HIV-1-infected patients, 793 in Chinese subjects: implicaotf iitso unses f or onist, 680 lack of pharmacokinetic interactions between evaluating CYP3A activity, 1413 Drug-dietary supplement cilomilast and theophylline or smoking in limited sampling strategy of S-warfarin concen- drug-drug, drug—dietary supplement, and drug— healthy volunteers, 1046 trations, but not warfarin S/R ratios, accu- citrus fruit and other food interactions: what lumiracoxib: pharmacokinetic and rately predicts S-warfarin AUC during base- have we learned? 559 pharmacodynamic profile when line and inhibition in CYP2C9 extensive Drug-drug interaction coadministered with fluconazole in healthy metabolizers, 570 “cocktail” approaches and strategies in drug de- subjects, 193 metabolism by n-acetyltransferase 1 in vitro and velopment: valuable tool or flawed science? meloxicam does not affect the antiplatelet effect in healthy volunteers: a prototype for tar- 120 of aspirin in healthy male and female volun- geted inhibition, 1406 drug-drug, drug—dietary supplement, and drug— teers, 777 no Clinically relevant CYP3A induction with the citrus fruit and other food interactions: what metabolism by n-acetyltransferase 1 in vitro and dual angiotensin-converting enzyme/neutral have we learned? 559 in healthy volunteers: a prototype for tar- endopeptidase inhibitor, M100240, 379 lack of interaction between enfuvirtide and geted inhibition, 1406 pharmacookf idenxteromtetihocrphsan after sin- ritonavir or ritonavir-boosted saquinavir in no pharmacokinetic or pharmacodynamic inter- gle or multiple dosing in combination with HIV-1-infected patients, 793 action between atorvastatin and the oral di- quinidine in extensive and poor rect thrombin inhibitor ximelagatran, 928 metabolizers, 1132 no Clinically relevant CYP3A induction with the dual angiotensin-converting enzyme/neutral no pharmacokinetic or pharmacodynamic inter- quinidinaes a probe for the role of P-glycoprotein endopeptidase inhibitor, M100240, 379 action between digoxin and the oral direct in the intestinal absorption and clinical ef- thrombin inhibitor ximelagatran in healthy fects of fentanyl, 224 Drug-herb interactions volunteers, 935 tacrolimus dosing in adult lung transplant pa- the effects of Ginkgo biloba extracts on the parecoxib sodium, an injectable COX-2-specific tients is related to cytochrome P4503A5 gene pharmacokinetics and pharmacodynamics of inhibitor, does not affect unfractionated hep- polymorphism, 135 donepezil, 538 arin-regulated blood coagulation parameters, Drug policy Drug interactions 474 could the WHO model list of essential medicines absence of a pharmacokinetic interaction be- a pharmacokinetic study of the combined admin- do more for the safe and appropriate use of in- tween etanercept and warfarin, 543 istration of amiodarone and ximelagatran, an jections? 1106 concomitant administration of lumiracoxib and a oral direct thrombin inhibitor, 1063 Drug safety triphasic oral contraceptive does not affect the pharmacokinetics and pharmacodynamics of cproonftirlae,c ep64t6i ve activity or pharmacokinetic txoirm, ealraeg autnraafnf,e ctaen d orbayl ad isriencgtl et hdroosem biofn a lcionhhiobli,- pharamraicpoipkrianzeotliec sf,o lltoowlienrga bilmiutlyt,i plaen d orasla fedtoys inogf in normal healthy volunteers, 179 the differential effects of steady-state 388 fluvoxamine on the pharmacokinetics of randomized crossover study investigating the in- pharmacokinetics and safety of solifenacin olanzapine and clozapine in healthy volun- fluence of ranitidine or omeprazole on the succinate in healthy young men, 1023 teers, 785 pharmacokinetics of cephalexin ECG readings dose-dependent alternations in the monohydrate, 1392 measuring the effects of supratherapeutic doses pharmacokinetics of olanzapine during renal interaction between itraconazole and of levofloxacin on healthy volunteers using coadministration of fluvoxamine in patients cimetidine, 919 four methods of QT correction and periodic with schizophrenia, 1386 and continuous ECG recordings, 464 simvastatin does not have a clinically significant effect of St. John’s wort on the pharmacokiuetics pharmacokinetic interaction with fenofibrate Education of theophylline in healthy volunteers, 95 in humans, 1054 benefits of individualized counseling by the the effects of once-daily saquinavir/minidose Drug metabolism pharmacist on the treatment outcomes of ritonavir on the pharmacokinetics of metha- “cocktail” approaches and strategies in drug de- hyperlipidemia in Hong Kong, 632 done, 293 velopment: valuable tool or flawed science? putting clinical pharmacology in context: the use effects of St. John’s wort (Hypericum perforatum) of popular movies, 30 120 on tacrolimus pharmacokinetics in healthy comparison of various urine collection intervals teaching application of clinical pharmacology volunteers, 89 for caffeine and dextromethorphan skills using unusual observations from human liver aldehyde oxidase: inhibition by 239 phenotyping in children, 708 clozapine overdoses, 141 drugs, 7 effect of St. John’s wort on the pharmacokinetics Efavirenz ibandronate: a clinical pharmacological and of theophylline in healthy volunteers, 95 induction of CYP3A4 be efavirenz in primary hu- pharmacokinetic update, 951 the effects of modifying in vivo cytochrome P450 man hepatocytes: comparison with rifampin indinavir and rifabutin drug interactions in 3A (CYP3A) activity on etoricoxib and phenobarbital, 1273 healthy volunteers, 305 pharmacokinetics and of etoricoxib adminis- Electroencephalography influence of azimilide on CYP2C19-mediated tration on CYP3A activity, 1125 kinetics and EEG effects of midazolam during metabolism, 373 evaluation of potential inductive effects of and after 1-minute, 1-hour, and 3-hour intra- influence of omeprazole on bioavailability of bis- aprepitant on cytochrome P450 3A4 and 2C9 venous infusions, 605 muth following administration of a tripie activity, 215 capsule of bismuth _ biskalcitrate, genetic polymorphisms of cytochrome P450 en- metronidazole, and tetracycline, 640 zymes and the effect on interindividual, Endogenous cortisol Extended-interval dosing a single-dose, two-way crossover, bioequivalence intranasal loteprednol etabonate in healthy male application of Bayes theorem to aminoglycoside- study of dexmethylphenidate HCl with and subjects: pharmacokinetics and effects of en- associated nephrotoxicity: comparison of ex- without food in healthy subjects, 173 dogenous cortisol, 510 tended-interval dosing, individualized Fosfluconazole Endothelia progenitor cells pharmacokinetic monitoring, and multiple- pharmacokinetics and safety of fosfluconazole af- effects of nicotine on the number and activity of daily dosing, 696 ter single intravenous bolus injection in circulating endothelial progenitor cells, 881 Fenofibrate healthy male Japanese volunteers, 284 Endothelin receptor simvastatin does not have a clinically significant Frovatriptan pharEmTa co-ksielneecttiicves eannddo tphehlairnm arceocdeyptnoarm iacnsta goofn itshte ipnh ahrummaacnosk,i ne1t0i5c4 interaction with fenofibrate pharmmiagcroakiinneeutrsi,c s 11o5f8 frovatriptan in adolescent SPP301 in healthy human subjects, 59 Fenoldopam FTY720 simulation of the impact of atropisomer dopamine-1 receptor agonist: renal effects and its multiple-dose FTY720: tolerability, interconversion on plasma exposure of potential role in the management of pharmacokinetics, and lymphocyte re- atropisomers of an endothelin receptor antag- radiocontrast-induced nephropathy, 1343 sponses in healthy subjects, 5: onist, 680 Fentanyl Gamma hydroxybutyrate Enfuvirtide quinidine as a probe for the role of P-glycoprotein pharmacokinetics of sodium oxybate oral solu- lack of interaction between enfuvirtide and in the intestinal absorption and clinical ef- tion following acute and chronic administra- ritonavir or ritonavir-boosted saquinavir in fects of fentanyl, 224 tion to narcoleptic patients, 253 HIV-1-infected patients, 793 Fexofenadine Garenoxacin Epilepsy central effects of fexofenadine and cetirizine: characterization of the penetration of lack of a clinically significant effect of measurement of psychomotor performance, garenoxacin into the breast milk of lactating zonisamide on phentyoin steady-state subjective sleepiness, and brain histamine women, 188 pharmacokinetics in patients with epilepsy, H -receptor occupancy using C-doxepin Gastric acid-related diseases 1230 positron emission tomography, 890 pharmacokinetic and pharmacodynamic evalua- oxcarbazepine pharmacokinetics and tolerability 5-HT3 receptor antagonist tion of a novel proton pump inhibitor, in children with inadequately controlled epi- pharmacokinetic and safety evaluation of YH1885, in healthy volunteers, 73 lepsy, 1290 palonosetron, a 5-hydroxytryptamine-3 re- GBD project safety, tolerability, and pharmacokinetic profile ceptor antagonist, in U.S. and Japanese of BIA 2-093, a novel putative antiepileptic, healthy subjects, 520 go lobal burden of disease (GBD) for hepatitisC , 20 in a rising multiple-dose study in young Fluconazole Gemtuzumab ozogamicin healthy humans, 906 lumiracoxib: pharmacokinetic and pharmaco- pharmacokinetics of gemtuzumab ozogamicin as Erythromycin breath test dynamic profile when coadministered with a single-agent treatment of pediatric patients the effects of modifying in vivo cytochrome P450 fluconazole in healthy subjects, 193 with refractory or relapsed acute myeloid leukemia, 873 3A (CYP3A) activity on etoricoxib pharmacokinetics and safety of fosfluconazole af- pharmacokinetics and of etoricoxib adminis- ter single intravenous bolus injection in Genetic polymorphisms tration on CYP3A activity, 1125 healthy male Japanese volunteers, 284 differences in drug pharmacokinetics between Erythropoietin Fluoropyrimidine East Asians and Caucasians and the role of ge- netic polymorphisms, 1083 pharmacokinetic and pharmacodynamic model- important role of the dihydrouracil/uracil ratio in ing of recombinant human erythropoietin af- marked _ interpatient variations of genetic polymorphisms of cytochrome P450 en- ter single and multiple doses in healthy vol- fluoropyrimidine pharmacokinetics and zymes and the effect on interindividual, unteers, 991 pharmacodynamics, 1260 pharmacokinetic variability in extensive Estrogen receptor Fluoxetine metabolizers, 447 Geriatric volunteers lack of attenuation in the antitumor effect of pharmacokinetics/pharmacodynamics of tamoxifen by chronic CYP isoform inhibi- desloratadine and fluoxetine in healthy vol- single-dose pharmacokinetics of daptomycin in tion, 861 unteers, 1252 young and geriatric volunteers, 612 ET -selective endothelin receptor antagonist Flurbiprofen utility of sparse concentration sampling for citalopram in elderly clinical trial subjects, pharmacokinetics and pharmacodynamics of the analgesic effect of sustained-release flurbiprofen ET -selective endothelin receptor antagonist administered at the site of tissue injury in the 1353 SPP301 in healthy human subjects, 59 oral surgery model, 1419 Ginkgo biloba Etanercept Fluvoxamine the effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of absence of a clinically relevant interaction be- the differential effects of steady-state donepezil, 538 tween etanercept and digoxin, 1244 fluvoxamine on the pharmacokinetics of absence of a pharmacokinetic interaction be- olanzapine and clozapine in healthy volun- Glucocorticoid therapy tween etanercept and warfarin, 543 teers, 785 MDR1 mRNA expressions in peripheral blood unaltered etanercept pharmacokinetics with con- dose-dependent alternations in the pharmaco- mononuclear cells of patients with ulcerative current methotrexate in patients with rheu- kinetics of olanzapine during coadministra- colitis in relation to glucocorticoid adminis- matoid athritis, 1235 tion of fluvoxamine in patients with schizo- tration, 481 Etoricoxib phrenia, 1386 Glucocorticoids effects of fluvoxamine on lansoprazole pharmacokinetics and pharmacodynamic re- the effects of modifying in vivo cytochrome P450 pharmacokinetics in relation to CYP2C19 ge- sponse of methylprednisolone in premeno- 3A (CYP3A) activity on etoricoxib notypes, 1223 pausal renal transplant recipients, 1003 pharmacokinetics and of etoricoxib adminis- tration on CYP3A activity, 1125 Food-drug interactions Glucocorticosteroids pharmacokinetics of etoricoxib in patients with effect of food on the pharmacokinetics of a dual intranasal loteprednol etabonate in healthy male renal impairment, 48 angiotensin-converting enzyme/neutral subjects: pharmacokinetics and effects of en- endopeptidase inhibitor, M100240, 1380 dogenous cortisol, 510 1436 e¢ J Clin Pharmacol 2004;44:1432-1442 Glucose control Hypertension Ketolide intense management of diabetes mellitus: role of blood pressure control and nephroprotection in pharmacokinetics and safety of the ketolide glucose control and antiplatelet agents, 414 diabetes, 431 telithromycin in patients with renal impair- Glucose intolerance optimizing dose selection with modeling and ment, 234 preventing type II diabetes mellitus, 406 simulation: application to the vasopeptidase Kidney transplantation Glycoprotein Itb/IIa inhibitor M100240, 621 pharmacokinetic study of mycophenolic acid in glycoprotein IIb/IIIa receptor antagonists and risk pharmacokinetics of M100240 and MDL Korean kidney transplant patients, 743 of bleeding: a single-center experience in 100,173, a dual angiotensin-converting en- Kinetics zyme/neutral endopeptidase inhibitor, in 1020 patients, 1328 kinetics and EEG effects of midazolam during healthy young and elderly volunteers, 901 GnRH and after 1-minute, 1-hour, and 3-hour intra- pharmacokinetics of treprostinil sodium admin- venous infusions, 605 pharmacokinetics and pharmacodynamics of a istered by 28-day chronic continuous subcu- novel depot formulation of abarelix, a gonad- taneous infusion, 503 Knee arthroplasty otropin-releasing hormone (GnRH) antago- efficacy of oxymorphone extended release in pharmacological and clinical profile of nist, in healthy men ages 50 to 75, 495 postsurgical pain: a randomized clinical trial moexipril: a concise review, 827 Haloperidol in knee arthroplasty, 767 Ibandronate intramuscular haloperidol or lorazepam and QT Lansoprazole ibandronate: a clinical pharmacological and intervals in schizophrenia, 1173 pharmacokinetic update, 951 effects of fluvoxamine on lansoprazole Hand-foot syndrome pharmacokinetics in relation to CYP2C19 ge- Ibuprofen hand-foot syndrome in patients treated with notypes, 1223 capecitabine-containing combination che- population pharmacokinetics of ibuprofen enan- Leukemia tiomers in very premature neonates, 1114 motherapy, 1166 pharmacokinetics of gemtuzumab ozogamicin as Imatinib Heparin a single-agent treatment of pediatric patients absolute bioavailability of imatinib (Glivec ) with refractory or relapsed acute myeloid parecoxib sodium, an injectable COX-2-specific orally versus intravenous infusion, 158 leukemia, 873 inhibitor, does not affect unfractionated hep- arin-regulated bleod coagulation parameters, Indinavir population pharmacokinetics of clofarabine, a 474 indinavir and rifabutin drug interactions in second-generation nucleoside analog, in pe- Hepatic function healthy volunteers, 305 diatric patients with acute leukemia, 1309 moderate liver impairment has no influence on Inhaled drugs Levofloxacin daptomycin pharmacokinetics, 715 estimating mass balance for inhaled drugs in hu- measuring the effects of supratherapeutic doses Hepatitis C mans: an example with a VLA-4 antagonist, of levofloxacin on healthy volunteers using IVL745, 348 four methods of QT correction and periodic global burden of disease (GBD) for hepatitisC ,2 0 and continuous ECG recordings, 464 Inhaled glucocorticoids pharmacokinetics and safety of viramidine, a Levosimendan prodrug of ribavirin, in healthy volunteers, risk-benefit value of inhaled glucocorticoids: a 265 pharmacokinetic/pharmacodynamic per- pharmacokinetics and pharmacodynamics of spective, 37 oral levosimendan and its metabolites in pa- Hepatocytes Insulin detemir tients with severe congestive heart failure: a induction of CYP3A4 be efavirenz in primary hu- dosing interval study, 1143 man hepatocytes: comparison with rifampin similarity of insulin detemir pharmacokinetics, Liver and phenobarbital, 1273 safety, and tolerability profiles in healthy Caucasian and Japanese American subjects, moderate liver impairment has no influence on Herb-drug interactions 258 daptomycin pharmacokinetics, 715 effect of St. John’s wort on the pharmacokinetics Interethnic variability serum metabolite/caffeine ratios as a test for liver of theophylline in healthy volunteers, 95 function, 338 Herbal medicine differences in drug pharmacokinetics between East Asians and Caucasianasnd the roolfe ge - Lorazepam the effects of Ginkgo biloba extracts on the netic polymorphisms, 1083 intramuscular haloperidol or lorazepam and QT pharmacokinetics and pharmacodynamics of Interindividual variability intervals in schizophrenia, 1173 donepezil, 538 interindividual and intraindividual variability of Loteprednol etabonate Histamine H1-receptor (H1R) the urinary 6B-hydroxycortisol/cortisol ratio intranasal loteprednol etabonate in healthy male central effects of fexofenadine and cetirizine: in Chinese subjects: implications of its use for subjects: pharmacokinetics and effects of en- measurement of psychomotor performance, evaluating CYP3A activity, 1413 dogenous cortisol, 510 subjective sleepiness, and brain histamine Intestinal absorption Lumiracoxib H -receptor occupancy using "'C-doxepin positron emission tomography, 890 quinidinaes a probe for the role of P-glycoprotein concomitant administration of lumiracoxib and a HIV in the intestinal absorption and clinical ef- triphasic oral contraceptive does not affect fects of fentanyl, 224 contraceptive activity or pharmacokinetic indinavir and rifabutin drug interactions in Irinotecan profile, 646 healthy volunteers, 305 influence of genetic variants in UGT1A1 and lumiracoxib: pharmacokinetic and pharmacokinetic and pharmacodynamic analy- UGT1A9 on the in vivo glucuronidation of pharmacodynamic profile when stihse raofp y aminp rHeInVa-v1i—ri-ncfoenctteadi nicnhgi ldrceonm, bi1n3a0t1i on ItraScNo-n3a8z,o le8 54 csuobajdemcitsn,i st1e9r3 ed with fluconazole in healthy Hyperlipidemia Lupus erythematosus renal interaction between itraconazole and benefits of individualized counseling by the cimetidine, 919 interactions of prednisolone and other pharmacist on the treatment outcomes of immunosuppressants used in dual treatment hyperlipidemia in Hong Kong, 632 Juvenile rheumatoid arthritis of systemic lupus erythematosus in lympho- clinical trials and lipid guidelines for type II dia- pharmacokinetics of meloxicam in patients with cyte proliferation assays, 1034 betes, 423 juvenile rheumatoid arthritis, 866 Lymphocyte proliferation assays Methadone colitis in relation to glucocorticoid adminis- interactions of prednisolone and other the effects of once-daily saquinavir/minidose tration, 481 immunosuppressants used in dual treatment ritonavir on the pharmacokinetics of metha- Montelukast of systemic lupus erythematosus in lympho- done, 293 pharmacokinetics of montelukast in asthmatic cyte proliferation assays, 1034 Methods patients 6 to 24 months old, 487 Lymphocyte response assessment of in vivo CYP2D6 activity: differen- Morbidity multiple-dose FTY720: tolerability, tial sensitivity of commonly used probes to epidemiology of diabetes, 397 pharmacokinetics, and lymphocyte re- urine pH, 1399 Movement disorders sponses in healthy subjects, 532 estimating mass balance for inhaled drugs in hu- single oral dose safety, tolerability, and M100240 mans: an example with a VLA-4 antagonist, pharmacokinetics of PNU-96391 in healthy effect of food on the pharmacokinetics of a dual IVL745, 348 volunteers, 276 angiotensin-converting enzyme/neutral evaluation of methods for improving precision of Movies endopeptidase inhibitor, M100240, 1380 blood pressure measurements in phase I clin- no clinically relevant CYP3A induction with the ical trials, 457 putting clinical pharmacology in context: the use of popular movies, 30 dual angiotensin-converting enzyme/neutral global burden of disease (GBD) for hepatitis C, 20 endopeptidase inhibitor, M100240, 379 limited sampling strategy of S-warfarin concen- Multiple-daily dosing pharmacokinetics of M100240 and MDL trations, but not warfarin S/R ratios, accu- application of Bayes theorem to aminoglycoside- 100,173, a dual angiotensin-converting en- rately predicts S-warfarin AUC during base- associated nephrotoxicity: comparison of ex- zyme/neutral endopeptidase inhibitor, in line and inhibition in CYP2C9 extensive tended-interval dosing, individualized healthy young and elderly volunteers, 901 metabolizers, 570 pharmacokinetic monitoring, and multiple- daily dosing, 696 Marijuana measuring the effects of supratherapeutic doses effect of acute marijuana on cardiovascular func- of levofloxacin on healthy volunteers using myocardial infarction tion and central nervous system four methods of QT correction and periodic questioning a class effect: does ACE inhibitor tis- pharmacokin° etic° s of » |1 5’ O|water: efrfeocte in oc- and continuous ECG recordings, 464 sue penetration influence the degree of casional and chronic users, 751 serum metabolite/caffeine ratios as a test for liver fibrinolytic balance alteration following an Mass balance function, 338 acute myocardial infarction? 150 estimating mass balance for inhaled drugs in hu- Methotrexate Mycophenolate mofetil mans: an example with a VLA-4 antagonist, unaltered etanercept pharmacokinetics with con- pharmacokinetic study of mycophenolic acid in IVL745, 348 current methotrexate in patients with rheu- Korean kidney transplant patients, 743 MDL 100,173 matoid athritis, 1235 N-acetylcystein pharmacokinetics of M100240 and MDL Methyl salicylate preventing contrast nephropathy: what is the best 100,173, a dual angiotensin-converting en- dermal absorption of camphor, menthol, and strategy? A review of the literature, 327 zyme/neutral endopeptidase inhibitor, in methyl salicylate in humans, 1151 Nanobudesonide healthy young and elderly volunteers, 901 Methylprednisolone the pharmacokinetics of nebulized nanocrystal MDR1 pharmacokinetics and pharmacodynamic re- budesonide suspension in healthy volun- tacrolimus dosing in adult lung transplant pa- sponse of methylprednisolone in teers, 67 tients is related to cytochrome P4503A5 gene premenopausal renal transplant recipients, Narcolepsy polymorphism, 135 1003 pharmacokinetics of sodium oxybate oral solu- Medicines Microgravity tion following acute and chronic administra- could the WHO model list of essential medicines physiological, pharmacokinetic, and tion to narcoleptic patients, 253 do more for the safe and appropriate use of in- pharmacodynamic changes in space, 837, NAT1 jections? 1106 pharmacokinetics, and pharmacodynamic metabolism by n-acetyltransferase 1 in vitro and Meloxicam changes in space, 837 in healthy volunteers: a prototype for tar- meloxicam does not affect the antiplatelet effect Midazolam geted inhibition, 1406 of aspirin in healthy male and female volun- evaluation of potential inductive effects of Neonates teers, 777 aprepitant on cytochrome P450 3A4 and 2C9 population pharmacokinetics of ibuprofen enan- pharmacokinetics of meloxicam in patients with activity, 215 tiomers in very premature neonates, 1114 juvenile rheumatoid arthritis, 866 kinetics and EEG effects of midazolam during NEP inhibition Menthol and after 1-minute, 1-hour, and 3-hour intra- effect of food on the pharmacokinetics of a dual venous infusions, 605 dermal absorption of camphor, menthol, and angiotensin-coverting enzyme/neutral methyl salicylate in humans, 1151 no clinically relevant CYP3A induction with the endopeptidase inhibitor, M100240, 1380 Metabolism dual angiotensin-converting enzyme/neutral no clinically relevant CYP3A induction with the endopeptidase inhibitor, M100240, 379 absorption of rivastigmine from different regions dual angiotensin-converting enzyme/neutral of the gastrointestinal tract in humans, 599 Migraine endopeptidase inhibitor, M100240, 379 Metabolizers pharmacokinetics of frovatriptan in adolescent optimizing dose selection with modeling and genetic polymorphisms of cytochrome P450 en- migraineurs, 1158 simulation: application to the vasopeptidase pharmacokinetics of sumatriptan nasal spray in inhibitor M100240, 621 zymes and the effect on interindividual, pharmacokinetic variability in extensive children, 359 Nephropathy metabolizers, 447 Modafinil preventing contrast nephropathy: what is the best pharmacokinetics of dextromethorphan after sin- effect of modafinil on acute pain: a randomized strategy? A review of the literature, 327 gle or multiple dosing in combination with double-blind crossover study, 1426 Neutral endopeptidase (NEP) quinidine in extensive and poor Molecular pharmacology pharmacokinetics of M100240 and MDL metabolizers, 1132 MDR1 mRNA expressions in peripheral blood 100,173, a dual angiotensin-converting en- mononuclear cells of patients with ulcerative zyme/neutral endopeptidase inhibitor, in healthy young and elderly volunteers, 901 1438 ¢ J Clin Pharmacol 2004;44:1432-1442

See more

The list of books you might like

Upgrade Premium
Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.
DMCA & Copyright: Dear all, most of the website is community built, users are uploading hundred of books everyday, which makes really hard for us to identify copyrighted material, please contact us if you want any material removed.
Copyright @ PDFdrive.to, 2022 | We love our users